EX-4.8





 Exhibit 4.8 
  

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)
WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. 
 DATED 1 June 2022 

GSK PLC 
 and 

PFIZER INC. 
 and 

HALEON PLC 
 and 

GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED 

and 
 GLAXOSMITHKLINE CONSUMER
HEALTHCARE HOLDINGS (NO.2) LIMITED 
  
  

DEED OF TAX COVENANT 
  

 
 Slaughter and
May 
 One Bunhill Row 
 London
EC1Y 8YY 
 (DER/SEZO) 
 Exhibits and schedules
have been omitted pursuant to the Instructions as to Exhibits in Form 20-F and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request. 












 CONTENTS 
  

							
	1.	  	Interpretation	  	 	3	
			
	2.	  	GSK Tax Covenant	  	 	18	
			
	3.	  	Pfizer Tax Covenant	  	 	19	
			
	4.	  	GSK and Pfizer Tax Covenants: Limitations	  	 	20	
			
	5.	  	Haleon Tax Covenant	  	 	24	
			
	6.	  	Haleon Tax Covenant: Limitations	  	 	25	
			
	7.	  	Costs and Expenses	  	 	28	
			
	8.	  	Mitigation	  	 	29	
			
	9.	  	Due Date of Payment	  	 	30	
			
	10.	  	Recovery	  	 	31	
			
	11.	  	Reliefs	  	 	33	
			
	12.	  	Conduct of Tax Authority Claims	  	 	34	
			
	13.	  	Tax Returns	  	 	39	
			
	14.	  	Transfer Pricing	  	 	45	
			
	15.	  	Tax Consolidations	  	 	46	
			
	16.	  	Post-Demerger Completion Conduct	  	 	49	
			
	17.	  	Project Cosmos	  	 	50	
			
	18.	  	Anti-hybrid rules and interest restriction rules	  	 	55	 
			
	19.	  	Miscellaneous	  	 	56	
			
	20.	  	Costs and Expenses	  	 	57	 
			
	21.	  	Governing Law and Jurisdiction	  	 	57	 
	
	SCHEDULES	 
		
	Schedule 1 - Post-Demerger Completion Conduct	  	 	58	 
		
	Schedule 2 - White List	  			
		
	Schedule 3 - Indirect CGT Reporting Procedure	  			














			
	THIS DEED is made on 1 June 2022	  	

 BETWEEN: 
  

	(1)	 GSK PLC, a public limited company incorporated in England with number 03888792, having its registered
office at 980 Great West Road, Brentford, Middlesex, TW8 9GS (“GSK”); 


  

	(2)	 PFIZER INC., a corporation incorporated under the laws of Delaware whose registered office is at 235
East 42nd Street, New York, New York 10017 (“Pfizer”);  


  

	(3)	 HALEON PLC, a public limited company incorporated in England with number 13691224, having its registered
office at 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS (“Haleon”); 


  

	(4)	 GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED, a private limited company incorporated under the
laws of England under registered number 08998608 whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS (“GSKCHHL”); and 



 

	(5)	 GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (NO.2) LIMITED, a private limited company incorporated
under the laws of England under registered number 11961650 whose registered office is at 980 Great West Road, Brentford, Middlesex TW8 9GS (“JVCo”), 



(each a “Party” and, together, the “Parties”); 

NOW THIS DEED WITNESSES as follows: 
  

	1.	 Interpretation 



 

	1.1	 In this Deed the following expressions shall have the following meanings: 



 

			
	“Accounts”	 	 means:
  

(a)   in relation to any company, its most recently finalised audited accounts as at the date of the
Demerger Agreement; and
  

(b)   the most recently finalised audited consolidated accounts of JVCo and its subsidiary
undertakings as at the date of the Demerger Agreement;

		
	“Affiliate”	 	has the meaning given to it in the SCIA;
		
	“Argentina Manufacturing Business”	 	has the meaning given to it in the Argentina NEBA;



  
 3 














			
		
	“Argentina NEBA”	 	has the meaning given to it in the SCIA;
		
	“ATB Companies”	 	 means:
  

(a)   GlaxoSmithKline Consumer Healthcare (UK) IP Limited;

 
 (b)   GlaxoSmithKline Consumer
Healthcare (UK) Trading Limited;
  

(c)   GSK Consumer Trading Services Limited;

 
 (d)   Stiefel Consumer
Healthcare (UK) Limited;
  

(e)   GlaxoSmithKline Panama S.A.;

 
 (f)   GSK CH Caricam Sociedad
de Responsabilidad Limitada;
  

(g)   GSK Consumer Healthcare Trinidad and Tobago Limited; and

 
 (h)   GlaxoSmithKline Consumer
Healthcare Vietnam Company Limited,
  
 and “ATB Company” shall mean
any one of them;

		
	“ATFA”	 	has the meaning given to it in the SCIA;
		
	“B Shares”	 	has the meaning given to it in the SCIA;
		
	“Balancing Payment”	 	means a payment made by a person to whom a Compensating Adjustment is available to a person who has suffered the Transfer Pricing Adjustment to which the Compensating Adjustment relates;
		
	“Business Day”	 	has the meaning given to it in the SCIA;
		
	“C Shares”	 	has the meaning given to it in the SCIA;
		
	“Chargeable Payment”	 	has the meaning given to it in s.1088 CTA 2010;
		
	“Compensating Adjustment”	 	means any Relief available to a person as a consequence of a Transfer Pricing Adjustment made in respect of another person;
		
	“Completion”	 	has the meaning given to it in the SCIA;



  
 4 














			
		
	“Constellation Tax Covenant”	 	means the Deed of Tax Covenant entered into between GSK, GSKCHHL and Novartis A.G. dated 2 March 2015;
		
	“Consumer Healthcare Business”	 	has the meaning given to it in the SCIA;
		
	“Conveyed Subsidiary”	 	has the meaning given to it in the ATFA;
		
	“Cosmos SAPA”	 	has the meaning given to it in the SCIA;
		
	“Cosmos SAPA Amendment Agreement”	 	has the meaning given to it in the SCIA;
		
	“Cosmos SCA”	 	has the meaning given to it in the SCIA;
		
	“Cosmos Seller Disclosure Letter”	 	has the meaning given to the term “Seller Disclosure Letter” in the Cosmos SAPA;
		
	“Costs”	 	has the meaning given to it in the SCIA;
		
	“CTA 2009”	 	means the Corporation Tax Act 2009;
		
	“CTA 2010”	 	means the Corporation Tax Act 2010;
		
	“Deferred Closing”	 	 means:
  

(a)   with respect to any GSK Delayed Company, completion of the transfer of such GSK Delayed
Company by the GSK Group to the Haleon Group; and
  

(b)   with respect to any Pfizer Delayed Company, completion of the transfer of such Pfizer Delayed
Company by the Pfizer Group to the Haleon Group;

		
	“Deferred GSK Conveyed Subsidiary”	 	has the meaning given to it in the GSK NEB Agreement;
		
	“Demerger”	 	has the meaning given to it in the SCIA;
		
	“Demerger Agreement”	 	means the Demerger Agreement entered into between GSK and Haleon on or around this date of this Deed;
		
	“Demerger Completion”	 	has the meaning given to it in the SCIA;



  
 5 














			
		
	“Directing Party”	 	 means:
  

(a)   where GSK shall bear the greater liability under this Deed in respect of the matter in
question, GSK; or

		
		 	 (b)   where Pfizer shall bear the greater liability under this Deed in respect
of the matter in question, Pfizer;

		
	“Event”	 	means any transaction, event, action or omission including, without limitation, Demerger Completion, Completion and any change in the residence of any person for the purposes of any Tax;
		
	“Exchange Agreements”	 	means the GSK Exchange Agreement, the Pfizer Exchange Agreement and the SLP Exchange Agreement;
		
	“Filing Date”	 	means, in relation to any Tax Return, the last date on which that Tax Return may be filed with the applicable Tax Authority either without incurring interest or penalties, or in order to ensure that such Tax Return is
effective;
		
	“Governmental Entity”	 	has the meaning given to it in the SCIA;
		
	“Group”	 	means the Haleon Group, the GSK Group and/or the Pfizer Group as the context demands;
		
	“GSK Argentina S.A.”	 	means GlaxoSmithKline Argentina S.A., a company incorporated under the laws of Argentina with registered address at Carlos Casares 3690, Victoria, San Fernando, B1644BCD, Province of Buenos Aires, Argentina;
		
	“GSK Business”	 	has the meaning given to it in the SCIA;
		
	“GSKCHH 3”	 	means GSK Consumer Healthcare Holdings (No.3) Limited, a private limited company incorporated in England with number 13401293, having its registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS;
		
	“GSKCHH 5”	 	means GSK Consumer Healthcare Holdings (No.5) Limited, a private limited company incorporated in England with number 13401372, having its registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS;
		
	“GSKCHH 6”	 	means GSK Consumer Healthcare Holdings (No.6) Limited, a private limited company incorporated in England with number 13401308, having its registered office at 980 Great West Road, Brentford, Middlesex, TW8
9GS;



  
 6 














			
		
	“GSK Delayed Companies”	 	means GSK Argentina S.A., the Conveyed Subsidiary and each Deferred GSK Conveyed Subsidiary;
		
	“GSK Exchange Agreement”	 	has the meaning given to it in the SCIA;
		
	“GSK Group”	 	 means GSK and its subsidiaries and subsidiary undertakings from time to time, excluding:

 
 (a)   Haleon and the Haleon
Group Companies; and
  

(b)   the GSK Delayed Companies,

 
 and the expressions “member of the GSK Group” and “GSK Group
Company” shall be construed accordingly;

		
	“GSK NEB Agreement”	 	has the meaning given to it in the SCIA;
		
	“GSK Relief”	 	 means:
  

(a)   any Relief of a GSK Group Company except for any Relief of a GSK Group Company which is a
Haleon Relief;




  
 7 














			
		
		 	 (b)   any Relief to which a GSK Group Company is entitled (or entitled to the
benefit of) under the Constellation Tax Covenant; and
  

(c)   any Relief to which a GSK Group Company is entitled (or entitled to the benefit of) under the
Cosmos SAPA;

		
	“GSK Share Exchange”	 	has the meaning given to it in the SCIA;
		
	“GSK Share Exchange Completion”	 	means completion of the GSK Share Exchange pursuant to and in accordance with the executed GSK Exchange Agreement;
		
	“GSK Tax Consolidation”	 	means any group, consolidation, fiscal unity or other arrangement for the purposes of any Tax which comprises both one or more GSK Group Companies and one of more Haleon Group Companies (whether in place by Law, agreement or
otherwise and including any group for the purposes of VAT) under which a member of the GSK Group is primarily responsible for paying or discharging Tax liabilities on behalf of, or Tax liabilities attributable to the Income, Profits or Gains of, or
Events affecting, that group, consolidation, fiscal unity or other arrangement (or the constituent members thereof), and/or for filing Tax Returns or claiming any Relief from Tax on behalf of or attributable to the same (but in all cases excluding
arrangements concerning US State Joint Tax Returns);
		
	“GSK Tax Liability”	 	 means:
  

(a)   a liability of any GSK Group Company to make or suffer an actual payment of Tax; and

 
 (b)   the use or set-off of any GSK Relief in circumstances where, but for the use or set-off, any GSK Group Company would have had an actual liability to Tax in respect of which GSK would
have been able to make a claim under clause 5.1 of this Deed (the amount of the GSK Tax Liability for these purposes being deemed to be equal to the amount of the actual liability to Tax that is saved by the use or set-off of the GSK Relief);

		
	“Haleon Group”	 	 means JVCo, Haleon, their respective subsidiaries and subsidiary undertakings from time to time and:

 
 (a)   the GSK Delayed
Companies; and




  
 8 














			
		
		 	 (b)   the Pfizer Delayed Companies,

 
 and the expressions “member of the Haleon Group” and “Haleon
Group Company” shall be construed accordingly;

		
	“Haleon Relief”	 	 means:
  

(a)   any Relief of a Haleon Group Company which arises as a consequence of or by reference to an
Event occurring (or deemed to occur) after Demerger Completion or in respect of a period or part period falling after Demerger Completion; or
  

(b)   any Relief of a Haleon Group Company which is shown as an asset of a Haleon Group Company in
the applicable Accounts,
  
 except any Relief of a Haleon Group Company which is a GSK
Relief by virtue of paragraph (b) or (c) of that defined term, or which is a Pfizer Relief by virtue of paragraph (b) of that defined term;

		
	“Haleon Tax Consolidation”	 	means any group, consolidation, fiscal unity or other arrangement for the purposes of any Tax which comprises both one or more GSK Group Companies and one of more Haleon Group Companies (whether in place by Law, agreement or
otherwise and including any group for the purposes of VAT) under which a member of the Haleon Group is primarily responsible for paying or discharging Tax liabilities on behalf of, or Tax liabilities attributable to the Income, Profits or Gains of,
or Events affecting, that group, consolidation, fiscal unity or other arrangement (or the constituent members thereof), and/or for filing Tax Returns or claiming any Relief from Tax on behalf of or attributable to the same (but in all cases
excluding arrangements concerning US State Joint Tax Returns);
		
	“Haleon Tax Liability”	 	 means:
  

(a)   a liability of any Haleon Group Company to make or suffer an actual payment of Tax; and

 
 (b)   the use or set-off of any Haleon Relief in circumstances where, but for the use or set-off, any




  
 9 














			
		 	Haleon Group Company would have had an actual liability to Tax in respect of which Haleon would have been able to make a claim under clause 2.1 and/or clause 3.1 of this Deed, as applicable (the amount of the Haleon
Tax Liability for these purposes being deemed to be equal to the amount of the actual liability to Tax that is saved by the use or set-off of the Haleon Relief);
		
	“HMRC”	 	means Her Majesty’s Revenue and Customs;
		
	“Income, Profits or Gains”	 	has the meaning given in clause 1.2(A);
		
	“Income Tax”	 	means any national, federal, state or local Tax imposed on or calculated by reference to net income or profits (however denominated), franchise Tax and other similar Tax;
		
	“Income Tax Return”	 	means any Tax Return in respect of Income Tax;
		
	“Indemnified Company”	 	has the meaning given in clause 9.1(A)(i);
		
	“Indirect CGT”	 	means any charge to Tax on a deemed disposal of an asset (including shares) imposed in the event of any indirect transfer or change of control of that asset (rather than a direct sale or other disposal of that asset by its immediate
owner), including any related interest, penalties or fines. For the avoidance of doubt, this includes circumstances in which there is a direct or indirect transfer of, or change of control in, the immediate owner of the asset in question;
		
	“Law”	 	means any statute, law, rule, regulation, ordinance, code or rule of common law issued, administered or enforced by any Governmental Entity, or any judicial or administrative interpretation thereof, including the rules of any stock
exchange or listing authority;
		
	“Non-Directing Party”	 	means whichever of GSK and Pfizer is not the Directing Party in relation to the matter in question;
		
	“PFCHHL”	 	means PF Consumer Healthcare Holdings LLC, a limited liability company incorporated under the laws of Delaware whose registered office is at 235 East 42nd Street, New York, New York 10017;
		
	“Pfizer Business”	 	has the meaning given to it in the SCIA;



  
 10 














			
		
	“Pfizer Delayed Companies”	 	means each of the “Deferred Conveyed Subsidiaries” as defined in the Pfizer NEB Agreement;
		
	“Pfizer Exchange Agreement”	 	has the meaning given in the SCIA;
		
	“Pfizer Group”	 	 means Pfizer and its subsidiaries and subsidiary undertakings from time to time, excluding:

 
 (a)   Haleon and the Haleon
Group Companies; and
  

(b)   the Pfizer Delayed Companies,

 
 and the expressions “member of the Pfizer Group” and “Pfizer
Group Company” shall be construed accordingly;

		
	“Pfizer NEB Agreement”	 	has the meaning given to it in the SCIA;
		
	“Pfizer Relief”	 	 means:
  

(a)   any Relief of a Pfizer Group Company except for any Relief of a Pfizer Group Company which is
a Haleon Relief; and
  

(b)   any Relief to which a Pfizer Group Company is entitled (or is entitled to the benefit of)
under the Cosmos SAPA;

		
	“Pfizer Share Exchange”	 	has the meaning given in the SCIA;



  
 11 














			
		
	“Pfizer Share Exchange Completion”	 	means completion of the Pfizer Share Exchange pursuant to and in accordance with the executed Pfizer Exchange Agreement;
		
	“Pfizer Tax Liability”	 	 means:
  

(a)   a liability of any Pfizer Group Company to make or suffer an actual payment of Tax; and

 
 (b)   the use or set-off of any Pfizer Relief in circumstances where, but for the use of set-off, any Pfizer Group Company would have had an actual liability to Tax in respect of which Pfizer
would have been able to make a claim under clause 5.3 of this Deed (the amount of the Pfizer Tax Liability for these purposes being deemed to be equal to the amount of the actual liability to Tax that is saved by the use of set-off of the Pfizer Relief);

		
	“Proceedings”	 	has the meaning given to it in the SCIA;
		
	“Relevant Percentage”	 	 means:
  

(a)   in respect of GSK, 68%; and

 
 (b)   in respect of Pfizer,
32%,
  
 and “Relevant Percentages” shall be construed
accordingly;

		
	“Relevant Time”	 	 means:
  

(a)   Demerger Completion;
  

(b)   in the case of a voluntary transaction, action or omission carried out, effected or made by
PFCHHL, Pfizer Share Exchange Completion; or
  

(c)   in the case of a voluntary transaction, action or omission carried out, effected or made by
any GSK Delayed Company or any Pfizer Delayed Company, Deferred Closing;




  
 12 














			
		
	“Relevant Time Limit”	 	means a time limit under applicable Law for a Tax Authority to open an enquiry or audit in respect of Tax, issue an assessment or impose any liability in respect of Tax, collect or enforce the collection of Tax, or take any similar
action;
		
	“Relief”	 	means any loss, allowance, credit, relief, deduction or set-off in respect of, or taken into account (or capable of being taken into account) in the calculation of a liability to, Tax, or any
right to a repayment of Tax;
		
	“Relief Surrender”	 	 means:
  

(a)   a surrender of any loss, allowance or other amount eligible for surrender by way of group
relief in accordance with the provisions of Part 5 or Part 5A of CTA 2010;
  

(b)   a reallocation of a gain or loss in accordance with section 171A TCGA; or

 
 (c)   a reallocation of a
chargeable realisation gain in accordance with section 792 CTA 2009,
  
 or, outside the
United Kingdom, any surrenders or reallocations corresponding to, or substantially similar to, any of the aforementioned surrenders or reallocations;

		
	“Reorganisation”	 	means all steps set out in the Steps Plan, except for those set out in modules D, E, G, R and S;
		
	“SCIA”	 	means the Separation Co-operation and Implementation Agreement between GSK, Pfizer, Haleon, JVCo, GSKCHHL and PFCHHL and entered into on or around the date of this Deed;
		
	“Separation Transaction”	 	has the meaning given to it in the SCIA;
		
	“SLPs” or “SLP”	 	has the meaning given to it in the SLP Exchange Agreement;
		
	“SLP Contribution”	 	means the steps set out in module S of the Steps Plan;
		
	“SLP Exchange Agreement”	 	has the meaning given in the SCIA;
		
	“SLP Share Exchange”	 	has the meaning given in the SCIA;



  
 13 














			
		
	“Steps Plan”	 	means the steps plan titled “Project Gold” prepared by KPMG and dated 30 May 2022 (with such amendments as have been agreed in writing between GSK, Pfizer and Haleon);
		
	“Sterling”	 	has the meaning given to it in the SCIA;
		
	“Straddle Period”	 	means any Tax Period beginning on or before, but ending after, Demerger Completion (or, in the case of PFCHHL only, any Tax Period beginning on or before, but ending after, Pfizer Share Exchange Completion);
		
	“Tax”	 	means all taxes, and all levies, duties, imposts, charges and withholdings in the nature of tax, including taxes on gross or net income, profits or gains and taxes on receipts, sales, use, employment, payroll, land, stamp, transfer,
occupation, franchise, value added, wealth and personal property, together with all penalties, charges, additions to tax, and interest relating to any of them, or to any late or incorrect return in respect of them, and regardless of whether any such
amounts are chargeable or attributable directly or primarily to any other person or are recoverable from any other person;
		
	“Tax Authority”	 	means any taxing, revenue or other authority competent to impose any liability to, or to assess or collect, any Tax, including, without limitation, HMRC and the Internal Revenue Service;
		
	“Tax Authority Claim”	 	means the issue of any notice, letter or other document by or on behalf of any Tax Authority or the taking of any other action by or on behalf of any Tax Authority (including any enquiry, claim, dispute, proceeding or other
engagement with a Tax Authority following therefrom) from which (in each case) it appears that a Haleon Tax Liability, GSK Tax Liability or Pfizer Tax Liability has arisen or may arise to (or is to be, or will be, imposed on) a member of the Haleon
Group, the GSK Group or the Pfizer Group (as the case may be);
		
	“Tax Consolidation”	 	means a GSK Tax Consolidation or a Haleon Tax Consolidation, as the case may be;
		
	“Tax Period”	 	means an accounting period or any other period in respect of which a Tax Return is required to be submitted to any Tax Authority;
		
	“Tax Return”	 	means any return, report, declaration, information return, statement or other document filed or required to be filed



  
 14 














			
		 	with any Tax Authority (including any schedule or attachment thereto and any amendment thereof), in connection with the determination, assessment or collection of any Tax or the administration of any Laws relating to any
Tax;
		
	“TCGA”	 	means the Taxation of Chargeable Gains Act 1992;
		
	“Transaction Document”	 	has the meaning given to it in the SCIA;
		
	“Transfer Pricing Adjustment”	 	means the computation of profits or losses for Tax purposes in relation to any transaction or series of transactions on a basis which substitutes arm’s length terms for the actual terms agreed, as finally determined by a Tax
Authority;
		
	“US State Joint Tax Returns”	 	means any super unitary state Tax Return filed or required to be filed with any Tax Authority of any state in the United States of America where such Tax Return includes both a member of the GSK Group and a member of the Haleon
Group (and, for the avoidance of doubt, this shall not include any combined federal Tax Returns in the United States of America);
		
	“VAT”	 	 means:
  

(a)   any value added tax imposed by the Value Added Tax Act 1994 and legislation and regulations
supplemental thereto;
  

(b)   to the extent not included in paragraph (a) above, any Tax imposed in compliance with the
council directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112); and
  

(c)   any other Tax of a similar nature to the Taxes referred to in paragraph (a) or paragraph
(b) above, whether imposed in the UK or a member state of the EU in substitution for, or levied in addition to, the Taxes referred to in paragraph (a) or paragraph (b) above or imposed elsewhere.



  

	1.2	 In this Deed, unless otherwise specified: 



 

	 	(A)	 references to: 


  

	 	(i)	 “Income, Profits or Gains” shall include any income, profits or gains which are deemed to be
earned, accrued or received for the purposes of any Tax; and 



  
 15 














	 	(ii)	 Income, Profits or Gains being earned, accrued or received on or before a particular date or in respect of a
particular period shall mean Income, Profits or Gains which are regarded as having been or are deemed to have been, earned, accrued or received on or before that date or in respect of that period; 



 

	 	(B)	 references to “period” are to a period of time and not to an accounting period unless the
phrase “accounting period” is used; 


  

	 	(C)	 references to “repayment of Tax” mean a repayment or refund of Tax paid or amounts paid for,
or on account of, Tax and shall be deemed to include any interest or repayment supplement on or in respect thereof; 


  

	 	(D)	 references to clauses, sub clauses, paragraphs, sub paragraphs, Schedules and Appendices are to clauses, sub
clauses, paragraphs, sub paragraphs of, and Schedules and Appendices to, this Deed; 


  

	 	(E)	 use of any gender includes other genders; 



 

	 	(F)	 references to a “company” shall be construed so as to include any corporation or other body
corporate, wherever and however incorporated or established; 


  

	 	(G)	 references to a “person” shall be construed so as to include any individual, firm, company,
corporation, body corporate, government, state or agency of a state, local or municipal authority or government body or any joint venture, association or partnership (whether or not having separate legal personality); 



 

	 	(H)	 references to a “holding company” or a “subsidiary” shall be construed as a
holding company or subsidiary (as the case may be) as defined in section 1159 of the Companies Act 2006; 


  

	 	(I)	 references to a “parent undertaking” shall be construed as a parent undertaking as defined in
section 1162 of the Companies Act 2006; 


  

	 	(J)	 a reference to any statute or statutory provision shall be construed as a reference to the same as it may have
been, or may from time to time be, amended, modified or re-enacted and shall include any subordinate legislation made from time to time under that statute or statutory provision, except to the extent that any
amendment or modification made after the date of this Deed would increase or alter the liability of any Party under this Deed; 


  

	 	(K)	 any reference to a “day” (including within the phrase “Business Day”) shall
mean a period of 24 hours running from midnight to midnight; 



  
 16 














	 	(L)	 references to times are to London time (unless otherwise stated); 



 

	 	(M)	 reference to “liabilities”, “costs” and/or “expenses ”
incurred by a person shall not include any amount in respect of VAT or any Tax of a similar nature included in such liabilities, costs and/or expenses for which that person or any other member of its Group is entitled to credit or repayment from any
Tax Authority; 


  

	 	(N)	 references to “indemnify” any person against any circumstance shall include indemnifying and
keeping such person harmless in respect of the matter in question and, unless otherwise specified, any indemnity given in this Deed shall be deemed to have been given on an after-Tax basis;



  

	 	(O)	 any indemnity or obligation to pay (the “Payment Obligation”) being given or assumed on an
“after-Tax basis” or expressed to be “calculated on an after-Tax basis” means that the amount payable pursuant to such Payment
Obligation (the “Payment”) shall be calculated in such a manner as will ensure that, after taking into account: 


  

	 	(i)	 any Tax required to be deducted or withheld from the Payment; 



 

	 	(ii)	 the amount and timing of any additional Tax which becomes payable (or would be payable but for the use of a
Relief) as a result of the Payment’s being subject to Tax; and 


  

	 	(iii)	 the amount and timing of any Tax benefit which is obtained, to the extent that such Tax benefit is attributable
to the matter giving rise to the Payment Obligation, 


  

	 	    	 the recipient of the Payment is in the same position as that in which it would have been if the matter giving
rise to the Payment Obligation had not occurred (or, in the case of a Payment Obligation arising by reference to a matter affecting a person other than the recipient of the Payment, the recipient of the Payment and that other person are, taken
together, in the same position as that in which they would have been had the matter giving rise to the Payment Obligation not occurred), provided that the amount of the Payment shall not exceed that which it would have been if it had been regarded
for all Tax purposes as received solely by the recipient and not any other person; and 


  

	 	(P)	 the rule known as the ejusdem generis rule shall not apply and accordingly: 



 

	 	(i)	 general words introduced by the word “other” shall not be given a restrictive meaning by reason of
the fact that they are preceded by words indicating a particular class of acts, matters or things; 


  

	 	(ii)	 general words shall not be given a restrictive meaning by reason of the fact that they are followed by
particular examples intended to be embraced by the general words; and 



  
 17 














	 	(Q)	 references to “writing” shall include any modes of reproducing words in a legible and non-transitory form, including email. 


  

	1.3	 In this Deed, unless otherwise specified: 



 

	 	(A)	 all headings and titles are inserted for convenience only and are to be ignored in the interpretation of this
Deed; and 


  

	 	(B)	 any schedules and appendices form part of this Deed and shall have the same force and effect as if expressly
set out in the body of this Deed, and any reference to this Deed shall include the schedules and appendices. 


  

	2.	 GSK Tax Covenant 



 

	2.1	 Subject to the other provisions of this Deed, GSK covenants with Haleon to pay to Haleon an amount equal, on an
after-Tax basis, to: 


  

	 	(A)	 any Haleon Tax Liability: 



 

	 	(i)	 arising directly as a consequence of: 



 

	 	(a)	 the GSK Share Exchange; 



 

	 	(b)	 the SLP Share Exchange; 



 

	 	(c)	 the SLP Contribution; 



 

	 	(d)	 the making of a Chargeable Payment by a GSK Group Company; 



 

	 	(e)	 any Haleon Group Company carrying on, at any time before Demerger Completion, any GSK Business (including any
Haleon Tax Liability arising directly as a consequence of any Income, Profits or Gains being earned, accrued or received as a result thereof); 


  

	 	(f)	 GSK Argentina S.A. carrying on: 



 

	 	(1)	 at any time before the “Commencement Date” (as defined in the Argentina NEBA), any Argentina
Manufacturing Business; or 


  

	 	(2)	 at any time before Deferred Closing, any GSK Business, 



 

	 	    	 including, in each case, any Haleon Tax Liability arising directly as a consequence of any Income, Profits or
Gains being earned, accrued or received as a result thereof; or 



  
 18 














	 	(g)	 the failure by a GSK Group Company at any time to comply with any of its obligations under this Deed or any
Transaction Document; 


  

	 	(ii)	 for which GSK would have been liable under clause 8 (Secondary Tax Liabilities) of the Cosmos SCA (had it
remained in effect, and had references to “Company” and “Company’s Group” therein been references to “Haleon” and “Haleon Group” as defined in this Deed as the context demands); 



 

	 	(iii)	 which comprises UK stamp duty or UK stamp duty reserve tax on the Demerger; or 



 

	 	(iv)	 in respect of a Haleon Tax Liability of GSKCHHL only, which arises directly as a consequence of:



  

	 	(a)	 any Event occurring on or before GSK Share Exchange Completion (or being deemed to occur on or before GSK Share
Exchange Completion for the purposes of any Tax); or 


  

	 	(b)	 any Income, Profits or Gains to the extent that such Income, Profits or Gains were earned, accrued or received
(A) on or before GSK Share Exchange Completion, or (B) in respect of a period ending on or before GSK Share Exchange Completion, and 


  

	 	(B)	 GSK’s Relevant Percentage of any Haleon Tax Liability arising directly as a consequence of:



  

	 	(i)	 the Reorganisation (or any part thereof); or 



 

	 	(ii)	 the Demerger, save for any Haleon Tax Liability which falls within clause 2.1(A)(iii).



  

	2.2	 Clause 2.1 shall be effective from (and including) Demerger Completion. 



 

	3.	 Pfizer Tax Covenant 



 

	3.1	 Subject to the other provisions of this Deed, Pfizer covenants with Haleon to pay to Haleon an amount equal, on
an after-Tax basis, to: 


  

	 	(A)	 any Haleon Tax Liability: 



 

	 	(i)	 arising directly as a consequence of: 



 

	 	(a)	 the Pfizer Share Exchange; 



  
 19 














	 	(b)	 any Haleon Group Company carrying on, at any time before Demerger Completion, any Pfizer Business (including
any Haleon Tax Liability arising directly as a consequence of any Income, Profits or Gains being earned, accrued or received as a result thereof); or 


  

	 	(c)	 the failure by a Pfizer Group Company at any time to comply with any of its obligations under this Deed or any
Transaction Document 


  

	 	(ii)	 for which Pfizer would have been liable under clause 8 (Secondary Tax Liabilities) of the Cosmos SCA (had it
remained in effect, and had references to “Company” and “Company’s Group” therein been references to “Haleon” and “Haleon Group” as defined in this Deed as the context demands); or 



 

	 	(iii)	 in respect of a Haleon Tax Liability of PFCHHL only, which arises directly as a consequence of:



  

	 	(a)	 any Event occurring on or before Pfizer Share Exchange Completion (or being deemed to occur on or before Pfizer
Share Exchange Completion for the purposes of any Tax); or 


  

	 	(b)	 any Income, Profits or Gains to the extent that such Income, Profits or Gains were earned, accrued or received
(A) on or before Pfizer Share Exchange Completion, or (B) in respect of a period ending on or before Pfizer Share Exchange Completion, and 


  

	 	(B)	 Pfizer’s Relevant Percentage of any Haleon Tax Liability arising directly as a consequence of:



  

	 	(i)	 the Reorganisation (or any part thereof); or 



 

	 	(ii)	 the Demerger, save for any Haleon Tax Liability which falls within clause 2.1(A)(iii).



  

	3.2	 Clause 3.1 shall be effective from (and including) Pfizer Share Exchange Completion.



  

	4.	 GSK and Pfizer Tax Covenants: Limitations 



 

	4.1	 Any covenant contained in clause 2.1 and clause 3.1 shall not apply to any Haleon Tax Liability
to the extent that: 


  

	 	(A)	 it has been provided for in the Accounts of any Haleon Group Company (other than in respect of GSKCHHL or
PFCHHL); 



  
 20 














	 	(B)	 it would not have arisen but for a voluntary transaction, action or omission carried out, effected or made by
any Haleon Group Company at any time after the Relevant Time other than, in each case, any such transaction, action or omission carried out, effected or made:  



 

	 	(i)	 in the ordinary course of the business or trade as carried on by such Haleon Group Company immediately prior to
the applicable Relevant Time; 


  

	 	(ii)	 at the written request of: 



 

	 	(a)	 in the case of any covenant contained in clause 2.1, a GSK Group Company; or



  

	 	(b)	 in the case of any covenant contained in clause 3.1, a Pfizer Group Company; or 



 

	 	(iii)	 as expressly required or expressly permitted under this Deed or any other Transaction Document,



  

	 	    	 and, for the avoidance of doubt (but without prejudice to clause 12), the act of disclosing information
(including the provision of any documentation) to a Tax Authority concerning any particular transaction, action or omission, shall not of itself constitute a “voluntary transaction, action or omission”; 



 

	 	(C)	 it arises in consequence of the making of a Chargeable Payment by a Haleon Group Company other than any such
Chargeable Payment made as expressly required or expressly permitted under any Transaction Document; 


  

	 	(D)	 it arises in consequence of any changes after the applicable Relevant Time of the date to which the relevant
Haleon Group Company makes up its accounts or in the bases, methods or policies of accounting of such Haleon Group Company; 


  

	 	(E)	 it has been made good without cost to any Haleon Group Company, including where such Taxes are paid or
discharged by a person other than a member of the Haleon Group (except where a member of the Haleon Group is required to reimburse such person for such payment or discharge); 



 

	 	(F)	 any Relief (other than a Haleon Relief and any Relief taken into account in clause 10 or clause
11) is available (at no cost to any Haleon Group Company) to relieve or mitigate such Haleon Tax Liability; 


  

	 	(G)	 it arises as a consequence of any failure by either Haleon at any time or any other Haleon Group Company after
the applicable Relevant Time to comply with any of its obligations under this Deed or any Transaction Document; 


  

	 	(H)	 any Haleon Group Company has otherwise made recovery in respect of that Haleon Tax Liability from a person
other than a Haleon Group Company (whether 



  
 21 














	 	
under this Deed, or by means of a claim under any provision of a Transaction Document, or by means of a claim under the Cosmos SAPA or Constellation Tax Covenant or otherwise); 


 

	 	(I)	 the Haleon Tax Liability constitutes interest, a penalty or a fine arising from a failure to pay Tax to a Tax
Authority within a reasonable time after GSK or Pfizer (as the case may be) has made a payment of an amount in respect of the relevant Taxes under clause 2.1 or clause 3.1 (as the case may be); 



 

	 	(J)	 in the case of the covenants contained in clause 2.1(A)(i)(e) and clause 3.1(A)(i)(b) only, the
relevant Income, Profits or Gains have accrued for the benefit of any Haleon Group Company (whether pursuant to any provision of the Cosmos SAPA, any Transaction Document or otherwise), there being no arrangements for the economic benefit of such
Income, Profits or Gains to be transferred to or otherwise enjoyed by (in the case of clause 2.1(A)(i)(e)) any GSK Group Company or (in the case of clause 3.1(A)(i)(b)) any Pfizer Group Company, save in each case to the extent such
Income, Profits or Gains have been provided for in or taken into account in the preparation of the Accounts of the relevant Haleon Group Company; 


  

	 	(K)	 in the case of the covenants contained in clause 2.1(A)(i)(e) and clause 3.1(A)(i)(b) only, the
liability is in relation to a Transfer Pricing Adjustment and the relevant Haleon Group Company is entitled to receive a Balancing Payment pursuant to clause 14, in which case the provisions of clause 14 shall apply in priority to
clause 2.1(A)(i)(e) and clause 3.1(A)(i)(b) (as applicable); 


  

	 	(L)	 such Haleon Tax Liability constitutes “Seller Indemnified Taxes” or “Purchaser Parent
Indemnified Taxes” (as such terms are defined in the Cosmos SAPA); 


  

	 	(M)	 such Haleon Tax Liability would not have arisen but for a change in the status as a taxpayer, residence or
deemed residence of Haleon for any Tax purposes due to a change in applicable Law that is made after Demerger Completion; or 


  

	 	(N)	 such Haleon Tax Liability is expressly allocated to a Haleon Group Company pursuant to the ATFA, the Argentina
NEBA or any other Transaction Document, provided that, in the case of the covenants contained in clause 2.1, such express allocation is as between a GSK Group Company and a Haleon Group Company and, in the case of the covenants contained in
clause 3.1, such express allocation is as between a Pfizer Group Company and a Haleon Group Company, and that in each case the express allocation is pursuant to an agreement to which both a member of the GSK Group or a member of the Pfizer
Group (as applicable) and a member of the Haleon Group are party.  


  

	4.2	 GSK and Pfizer each agree with Haleon that to the extent GSK (or any member of its Group) or Pfizer (or any
member of its Group) has a statutory or other right to recover any amount falling within the covenants at clause 2.1(A)(ii) or clause 3.1(A)(ii), as the case may be, against Haleon (or a member of the Haleon Group) then, to the extent
that the same has given rise to a payment under such aforementioned clauses of this Deed, or 



  
 22 














	 	
under Section 6.5(d) of the Cosmos SAPA, GSK or Pfizer (as the case may be) shall not, and shall procure (respectively) that the relevant member of the GSK Group and any member of the Pfizer
Group shall not, make any claim under such statutory or other right or take any other action to enforce such statutory or other right of recovery. 

  

	4.3	 To the extent that a claim could (apart from this clause 4.3) be made by Haleon:



  

	 	(A)	 against GSK under both clause 2.1(A) and clause 2.1(B), a claim may be brought only under
clause 2.1(A); or 


  

	 	(B)	 against Pfizer under both clause 3.1(A) and clause 3.1(B), a claim may be brought only under
clause 3.1(A). 


  

	4.4	 Save in circumstances where clause 4.10, clause 4.11 and/or clause 4.12 mean that a claim
in relation to a particular matter may only be made against GSK or against Pfizer under clause 2.1(B) or clause 3.1(B) respectively, Haleon may make a claim against GSK under clause 2.1(B) only if it makes a claim in respect of
the same matter against Pfizer under clause 3.1(B) (and vice versa). 


  

	4.5	 Haleon shall conduct any discussion, negotiation, settlement or dispute of any claim (or potential claim) it
may have against GSK under clause 2.1(B) and Pfizer under clause 3.1(B) in respect of the same matter in good faith and shall deal with each of GSK and Pfizer in a consistent manner. 



 

	4.6	 The parties acknowledge that GSK and Pfizer shall each be entitled to jointly
co-operate, co-ordinate, discuss and respond to any claim by Haleon under clause 2.1(B) and clause 3.1(B) and shall be entitled to share with each other
such information as may be necessary or expedient in connection with the same. 


  

	4.7	 No claim may be brought under clause 2.1 or clause 3.1 against GSK or Pfizer (respectively)
unless Haleon shall have given to (in the case of a claim under clause 2.1) GSK or (in the case of a claim under clause 3.1) Pfizer written notice of such claim specifying (in detail that is reasonable in the circumstances) the matter
which gives rise to the claim, the nature of the claim and the amount claimed in respect thereof on or before the date falling 30 days after the expiry of the period specified by statute during which an assessment of the relevant Tax liability may
be issued by the relevant Tax Authority or, if there is no such period, the date falling six years and 30 days after the end of the accounting period of the relevant Haleon Group Company in which Completion occurs. 



 

	4.8	 GSK shall not be liable in respect of any individual claim under clause 2.1(A), and Pfizer shall not be
liable in respect of an individual claim under clause 3.1(A), for less than [***] but once the amount of any such claim has exceeded such sum, GSK or Pfizer (as applicable) shall be liable in respect of the full amount of such claim and not
only the amount by which such sum is exceeded. For the purposes of this clause 4.8, individual claims arising out of the same or substantially the same matters, facts or circumstances shall be aggregated so as to be treated as a single claim.




  
 23 














	4.9	 Neither GSK nor Pfizer shall be liable for any individual claim in respect of the same matter under
(respectively) clause 2.1(B) and clause 3.1(B) (“Parallel Claims”) unless the aggregate liability of GSK and Pfizer in respect of those Parallel Claims is equal to or exceeds [***]. If the quantum of any Parallel
Claims is equal to or exceeds such threshold, GSK and Pfizer shall each be liable in respect of the full amount of such claims under clause 2.1(B) or clause 3.1(B) (as applicable) and not only any applicable excess. For the purposes of
this clause 4.9, individual claims arising out of the same or substantially the same matters, facts or circumstances shall be aggregated so as to be treated as a single claim. 



 

	4.10	 Pfizer shall have no liability in respect of any claim under clause 3.1(B)(i) in respect of a matter
that does not concern Indirect CGT (a “Non-Indirect CGT Claim”) unless and until the aggregate amount that Haleon could have claimed from Pfizer in respect of any such Non-Indirect CGT Claims in the absence of this clause 4.10 would have exceeded [***], in which event Pfizer shall thereafter be liable under clause 3.1(B)(i) for such amounts which exceed that [***]
threshold (and not for the full amount of such claims). 


  

	4.11	 The total aggregate liability of GSK in respect of any claim or claims under clause 2.1(B)(i) shall
not exceed [***], save that this clause 4.11 shall not apply in respect of any claim or claims under clause 2.1(B)(i) to the extent the same concerns Indirect CGT. 



 

	4.12	 The total aggregate liability of Pfizer in respect of any claim or claims under clause 3.1(B)(i) shall
not exceed [***], save that this clause 4.12 shall not apply in respect of any claim or claims under clause 3.1(B)(i) to the extent the same concerns Indirect CGT. 



 

	5.	 Haleon Tax Covenant 



 

	5.1	 Subject to the other provisions of this Deed, Haleon covenants with GSK to pay GSK an amount equal, on an after-Tax basis, to any GSK Tax Liability arising directly as a consequence of: 


  

	 	(A)	 any matter described in clause 8.1 or clause 8.3 of the Cosmos SCA and for which Haleon would be liable to GSK
under such provisions (had clause 8 (Secondary Tax Liabilities) of the Cosmos SCA remained in effect, and had references to “GSK” and “GSK’s Group” therein been references to “Haleon” and “Haleon Group”,
and had references to “Company” and “Company’s Group” therein been references to “GSK” and “GSK Group” as defined in this Deed as the context demands); 



 

	 	(B)	 any GSK Group Company carrying on, at any time before Demerger Completion, any Consumer Healthcare Business
(including any GSK Tax Liability arising directly as a consequence of any Income, Profits or Gains being earned, accrued or received as a result thereof); 



  
 24 














	 	(C)	 any failure by either Haleon at any time or any other Haleon Group Company after the applicable Relevant Time
to comply with any of its obligations under this Deed or any Transaction Document; and 


  

	 	(D)	 the making of a Chargeable Payment by any Haleon Group Company other than any such Chargeable Payment made as
expressly required or expressly permitted under any Transaction Document. 


  

	5.2	 Clause 5.1 shall be effective from (and including) Demerger Completion. 



 

	5.3	 Subject to the other provisions of this Deed, Haleon covenants with Pfizer to pay Pfizer an amount equal, on an
after-Tax basis, to any Pfizer Tax Liability arising directly as a consequence of: 


  

	 	(A)	 any matter described in clause 8.2 or clause 8.4 of the Cosmos SCA and for which Haleon would be liable to
Pfizer under such provisions (had clause 8 (Secondary Tax Liabilities) of the Cosmos SCA remained in effect, and had references to “Pfizer” and “Pfizer’s Group” therein been references to “Haleon” and “Haleon
Group” as defined in this Deed, and had references to “Company” and “Company’s Group” therein been references to “Pfizer” and “Pfizer’s Group” as defined in this Deed as the context demands);



  

	 	(B)	 any Pfizer Group Company carrying on, at any time before Demerger Completion, any Consumer Healthcare Business
(including any Pfizer Tax Liability arising directly as a consequence of any Income, Profits or Gains being earned, accrued or received as a result thereof); and 



 

	 	(C)	 any failure by either Haleon at any time or any other Haleon Group Company after Demerger Completion to comply
with any of its obligations under this Deed or any Transaction Document. 


  

	5.4	 Clause 5.3 shall be effective from (and including) Demerger Completion. 



 

	6.	 Haleon Tax Covenant: Limitations 



 

	6.1	 Any covenant contained in clause 5.1 and clause 5.3 shall not apply to any GSK Tax Liability or
any Pfizer Tax Liability respectively to the extent that: 


  

	 	(A)	 it would not have arisen but for a voluntary transaction, action or omission carried out, effected or made by
(in the case of clause 5.1) any GSK Group Company or (in the case of clause 5.3) any Pfizer Group Company, at any time or, for the purposes of clause 5.1(B) and clause 5.3(B) only, at any time after Demerger Completion, other than any
such transaction, action or omission carried out, effected or made: 


  

	 	(i)	 in the ordinary course of the business or trade as carried on by (in the case of clause 5.1) a GSK Group
Company or (in the case of clause 5.3) a Pfizer Group Company immediately prior to Demerger Completion; 


  

	 	(ii)	 at the written request of any Haleon Group Company; or 



  
 25 














	 	(iii)	 as expressly required or expressly permitted under this Deed, 



 

	 	    	 and, for the avoidance of doubt (but without prejudice to clause 12), the act of disclosing information
(including the provision of any documentation) to a Tax Authority concerning any particular transaction, action or omission, shall not of itself constitute a “voluntary transaction, action or omission”; 



 

	 	(B)	 it arises in consequence of any changes at any time or, for the purposes of clause 5.1(B) and clause 5.3(B)
only, after Demerger Completion, of the date to which (in the case of clause 5.1) a GSK Group Company or (in the case of clause 5.3) a Pfizer Group Company, makes up its accounts or in the bases, methods or policies of accounting of
any (in the case of clause 5.1) GSK Group Company or (in the case of clause 5.3) Pfizer Group Company; 


  

	 	(C)	 it has been made good without cost to (in the case of clause 5.1) any GSK Group Company or (in the case
of clause 5.3) any Pfizer Group Company, including where such Taxes are paid or discharged by a person other than a member of (in the case of clause 5.1) the GSK Group or (in the case of clause 5.3) the Pfizer Group (except
where a member of the GSK Group or Pfizer Group, as applicable, is required to reimburse such person for such payment or discharge); 


  

	 	(D)	 any Relief other than: 



 

	 	(i)	 (in the case of clause 5.1) a GSK Relief or (insofar as such clauses concern GSK) any Relief taken into
account in clause 10 or clause 11; or 


  

	 	(ii)	 (in the case of clause 5.3) a Pfizer Relief or (insofar as such clauses concern Pfizer) any Relief taken
into account in clause 10 or clause 11, 


  

	 	    	 is available to relieve or mitigate such GSK Tax Liability or Pfizer Tax Liability (as applicable);



  

	 	(E)	 the GSK Tax Liability or Pfizer Tax Liability (as applicable) constitutes interest, a penalty or a fine arising
from a failure to pay Tax to a Tax Authority within a reasonable time after Haleon has made a payment of an amount in respect of the relevant Taxes under clause 5.1 or clause 5.3 (as the case may be); 



 

	 	(F)	 it arises as a consequence of any failure by (in the case of clause 5.1) any GSK Group Company or (in
the case of clause 5.3) any Pfizer Group Company to comply with any of its obligations under this Deed or any Transaction Document; 


  

	 	(G)	 either (in the case of clause 5.1) any GSK Group Company or (in the case of clause 5.3) any
Pfizer Group Company has otherwise made recovery in respect of that GSK Tax Liability or Pfizer Tax Liability (as applicable) from a person other than a GSK Group Company or Pfizer Group Company (as applicable), whether under this Deed, or by means
of a claim under any provision of any Transaction Document or otherwise; 



  
 26 














	 	(H)	 in the case of the covenants contained in clause 5.1(B) and clause 5.3(B) only:



  

	 	(i)	 a member of the Haleon Group would have been entitled to make a claim (in the case of a GSK Tax Liability)
against GSK under Section 6.5(d)(ii) of the Cosmos SAPA or (in the case of a Pfizer Tax Liability) against Pfizer under Section 6.5(d)(i) of the Cosmos SAPA had the relevant liability to Tax arisen to a Haleon Group Company instead of a
GSK Group Company or a Pfizer Group Company (as applicable); 


  

	 	(ii)	 the relevant Income, Profits or Gains (and the liability to Tax in relation thereto) shall be economically
borne by a Haleon Group Company pursuant to the GSK NEB Agreement, the Pfizer NEB Agreement or any arrangement with a similar economic effect; or 


  

	 	(iii)	 the relevant Income, Profits or Gains have accrued for the benefit of (in the case of clause 5.1(B)) any
GSK Group Company or (in the case of clause 5.3(B)) any Pfizer Group Company, there being no arrangements for the economic benefit of such Income, Profits or Gains to be transferred to or otherwise enjoyed by any Haleon Group Company;



  

	 	(I)	 in the case of the covenants contained in clause 5.1(B) and clause 5.3(B), the liability is in
relation to a Transfer Pricing Adjustment and the relevant GSK Group Company or Pfizer Group Company (as applicable) is entitled to receive a Balancing Payment pursuant to clause 14, in which case the provisions of clause 14
shall apply in priority to clause 5.1(B) and clause 5.3(B) (as applicable); or 


  

	 	(J)	 in the case of a GSK Tax Liability, such GSK Tax Liability is expressly allocated to a GSK Group Company
pursuant to the ATFA, the Argentina NEBA or any other Transaction Document, provided that such express allocation is as between a GSK Group Company and a Haleon Group Company and that the express allocation is pursuant to an agreement to which both
a member of the GSK Group and a member of the Haleon Group are party; or 


  

	 	(K)	 such GSK Tax Liability or Pfizer Tax Liability (as applicable) would not have arisen but for a change in the
status as a taxpayer, residence or deemed residence of Haleon for any Tax purposes due to a change in applicable Law that is made after Demerger Completion.  



 

	6.2	 Haleon agrees with each of GSK and Pfizer that to the extent Haleon (or any member of its Group) has a
statutory or other right to recover any amount falling within the covenants at clause 5.1(A) or clause 5.3(A) against (in the case of clause 5.1(A)) GSK or a member of the GSK Group or (in the case of clause 5.3(A))
Pfizer or a member of the Pfizer Group then, to the extent that the same has given rise to a payment under such aforementioned clauses of this Deed, Haleon shall not, and shall procure that the relevant member of the Haleon Group shall not, make any
claim under such statutory or other right or take any other action to enforce such statutory or other right of recovery. 



  
 27 














	6.3	 No claim may be brought under clause 5.1 or clause 5.3 against Haleon unless (in the case of
clause 5.1) GSK or (in the case of clause 5.3) Pfizer shall have given to Haleon written notice of such claim specifying (in detail that is reasonable in the circumstances) the matter which gives rise to the claim, the nature of
the claim and the amount claimed in respect thereof on or before the date falling 30 days after the expiry of the period specified by statute during which an assessment of the relevant Tax liability may be issued by the relevant Tax Authority or, if
there is no such period, the date falling six years and 30 days after the end of the accounting period of the relevant GSK Group Company or Pfizer Group Company (as applicable) in which Demerger Completion occurs. 



 

	6.4	 Haleon shall not be liable in respect of any individual claim under clause 5.1 or clause 5.3, for
less than [***], but once the amount of any such claim has exceeded such sum, Haleon shall be liable in respect of the full amount of such claim and not only the amount by which such sum is exceeded. For the purposes of this clause 6.4,
individual claims arising out of the same or substantially the same matters, facts or circumstances shall be aggregated so as to be treated as a single claim. 



 

	7.	 Costs and Expenses 



 

	7.1	 Subject to clause 7.3, GSK hereby covenants to pay to Haleon an amount equal, on an after-Tax basis, to any Costs properly incurred or payable by a Haleon Group Company in connection with or in consequence of (i) any Haleon Tax Liability referred to in clause 2.1 to the extent that it
gives rise to an obligation for GSK to make a payment under clause 2.1, or (ii) in successfully taking any action under clause 2.1.  



 

	7.2	 Subject to clause 7.3, Pfizer hereby covenants to pay to Haleon an amount equal, on an after-Tax basis, to any Costs properly incurred or payable by a Haleon Group Company in connection with or in consequence of (i) any Haleon Tax Liability referred to in clause 3.1 to the extent that it
gives rise to an obligation for Pfizer to make a payment under clause 3.1, or (ii) in successfully taking any action under clause 3.1.  



 

	7.3	 GSK and Pfizer each separately covenant to pay to Haleon an amount equal, on an after-Tax basis, to its Costs
Proportion of any Costs properly incurred or payable by a Haleon Group Company in connection with or in consequence of (i) any Haleon Tax Liability referred to in clause 2.1(B) and clause 3.1(B) to the extent that it gives rise to an obligation for
both of GSK and Pfizer to make a payment under clause 2.1(B) and clause 3.1(B) (respectively) (ignoring for these purposes the application of clause 4.10), or (ii) in successfully taking any action against both of GSK and Pfizer under clause 2.1(B)
and clause 3.1(B) (respectively). For the purposes of this clause 7.3, GSK or Pfizer’s (as applicable) “Costs Proportion” shall mean the proportion of the relevant Haleon Tax Liability referred to in clause 2.1(B) and clause 3.1(B)
that is payable by GSK or Pfizer respectively (and for the avoidance of doubt taking into account the application of clause 4.10 to clause 4.12 (inclusive)). 


  


	7.4	 Haleon hereby covenants to pay: 



 

	 	(A)	 to GSK an amount equal, on an after-Tax basis, to any Costs properly
incurred or payable by a GSK Group Company in connection with or in consequence of (i) any GSK Tax Liability referred to in clause 5.1 to the extent that it gives rise to an obligation for Haleon to make a payment under clause
5.1, or (ii) in successfully taking any action under clause 5.1. 



  
 28 














	 	(B)	 to Pfizer an amount equal, on an after-Tax basis, to any Costs properly
incurred or payable by a Pfizer Group Company in connection with or in consequence of (i) any Pfizer Tax Liability referred to in clause 5.3 to the extent that it gives rise to an obligation for Haleon to make a payment under
clause 5.3, or (ii) in successfully taking any action under clause 5.3. 


  

	8.	 Mitigation 


  

	8.1	 Subject to clause 8.2, the Indemnified Party shall, at the direction in writing of the Indemnifying
Party (acting reasonably) and subject to the Indemnifying Party indemnifying and securing the Indemnified Party on an after-Tax basis against all Costs which may thereby be incurred: 



 

	 	(A)	 take, or procure that any other member of the Indemnified Party’s Group shall take, all such steps as the
Indemnifying Party may require to: 


  

	 	(i)	 make, or procure that any member of the Indemnifying Party’s Group makes, a Relief Surrender; or



  

	 	(ii)	 otherwise surrender or transfer, or procure that any other member of the Indemnifying Party’s Group
surrenders or transfers, so far as permitted by Law, any Relief to any member of the Indemnified Party’s Group, 


  

	 	    	 in each case for no consideration; 



 

	 	(B)	 use, or procure that another member of the Indemnified Party’s Group shall use, all such Reliefs
including, without limitation, Reliefs made available in accordance with clause 8.1 but (in all cases) excluding any Indemnified Party’s Relief; and 



 

	 	(C)	 make, or procure that another member of the Indemnified Party’s Group shall make, all claims and elections
specified by the Indemnifying Party, 


  

	 	    	 in each case so as to reduce, eliminate or make good any Tax Liability for which the Indemnifying Party would
otherwise be liable under clause 2, clause 3 or clause 5 (as applicable), provided that nothing in this clause 8.1 shall require any member of an Indemnified Party’s Group to use (i) any Indemnified Party’s
Relief, or (ii) any Relief to the extent it has already been taken into account for the purposes of clause 10 or clause 11, and that the Indemnified Party shall, for the avoidance of doubt, not be considered to be acting
reasonably in making a direction for the purposes of this clause 8.1 to the extent such direction directs an action by the Indemnified Party’s Group that is reasonably expected to increase the Tax Liabilities of such Indemnified
Party’s Group for which it is not indemnified (whether under this Deed, any Transaction Document, the Cosmos SAPA, the Constellation Tax Covenant or otherwise). 



 

	8.2	 In the event that both GSK and Pfizer are Indemnifying Parties and any directions from GSK and Pfizer under
clause 8.1 shall conflict, the direction of the Indemnifying Party which is also the Directing Party shall prevail, provided that the Directing Party shall consult with the Non-Directing Party in good
faith before any direction is given under 



  
 29 














	 	
clause 8.1. Where GSK and Pfizer remain unable to agree despite such consultation, the Directing Party shall in good faith take into account and reflect any suggestions or comments from
the Non-Directing Party concerning the matter and procure that they are reflected in any action or inaction which is ultimately decided upon to the extent that they are reasonable. 


 

	8.3	 For the purposes of clause 8 only: 



 

	 	(A)	 “Indemnified Party” shall mean the Party that would be entitled to make the applicable claim
under clause 2, clause 3 or clause 5; 


  

	 	(B)	 “Indemnifying Party” shall mean the Party that would be liable with respect to the applicable
claim under clause 2, clause 3 or clause 5; 


  

	 	(C)	 “Indemnified Party’s Group” and “Indemnifying Party’s Group” shall
mean the Haleon Group, the GSK Group or the Pfizer Group according to the identity of the Indemnified Party and the Indemnifying Party respectively; and 


  

	 	(D)	 “Indemnified Party’s Relief” shall mean a Haleon Relief, a GSK Relief or a Pfizer Relief
according to the identity of the Indemnified Party; and 


  

	 	(E)	 “Tax Liability” shall mean the Haleon Tax Liability, the GSK Tax Liability or the Pfizer Tax
Liability as the context demands. 


  

	9.	 Due Date of Payment 



 

	9.1	 Where any party becomes liable to make any payment pursuant to clause 2, clause 3,
clause 5 or clause 7 of this Deed, the due date for the making of that payment shall be: 


  

	 	(A)	 in a case which involves an actual payment of Tax, the later of: 



 

	 	(i)	 the date falling 10 Business Days prior to the last date on which the member of the relevant Group whose
liability to Tax has given rise to the relevant payment pursuant to clause 2, clause 3 or clause 5 of this Deed (the “Indemnified Company”) would have had to have paid the Tax that has given rise to the
liability under this Deed in order to avoid incurring a liability to interest or a charge or penalty in respect of that liability; and 


  

	 	(ii)	 the date falling 10 Business Days after the party which is liable to make the payment under this Deed has been
notified of its liability by the other party; 


  

	 	(B)	 in a case which involves the setting off of a right to repayment of Tax or the utilisation of Relief, the later
of: 


  

	 	(i)	 the date falling 10 Business Days prior to the last date on which the Indemnified Company would have had to
have paid the Tax against which the repayment that has given rise to the liability under this Deed has been 



  
 30 














	 	
set off or which would have been paid but for the utilisation of the Relief (as the case may be) in order to avoid incurring a liability to interest or a charge or penalty in respect of that
liability; and 

  

	 	(ii)	 the date falling 10 Business Days after the party which is liable to make the payment under this Deed has been
notified of its liability by the other party; and 


  

	 	(C)	 in a case which involves a payment pursuant to clause 7, the date falling 10 Business Days after the
party which is liable to make the payment under the relevant clause has been notified of its liability by the Indemnified Company. 


  

	10.	 Recovery 


  

	10.1	 Where a Haleon Group Company is entitled to recover from any other person (other than a GSK Group Company or a
Haleon Group Company, but including a Tax Authority) any sum in respect of any matter which has given rise to an obligation of: 


  

	 	(A)	 GSK to make a payment under clause 2.1(A); or 



 

	 	(B)	 GSK to make a payment under clause 2.1(B), but not of Pfizer to make a payment under clause
3.1(B), 


 then Haleon shall procure that the relevant Haleon Group Company shall (if requested by and subject to GSK
indemnifying and securing the relevant Haleon Group Company on an after-Tax basis against all losses, fines, penalties, interest, charges and Costs which may thereby be incurred (for the purposes of clause
10.11, a “Costs Indemnity”)) take such action as GSK shall reasonably request in writing, with reasonable notice (taking into account the requirements of clause 10.2 and clause 10.11), to enforce such recovery
against the person in question and Haleon shall procure that the relevant Haleon Group Company shall account to GSK for any Recovered Amounts up to an amount not exceeding the amount paid by GSK under clause 2.1(A) or clause 2.1(B) in
respect of the relevant matter. 
  

	10.2	 If Haleon considers (acting reasonably and in good faith) that any action requested by GSK in accordance with
clause 10.1 has or is likely to have a material and negative impact on the relationship between a Haleon Group Company and a Tax Authority or is or is likely to be materially prejudicial to a Haleon Group Company’s business,
clause 10.11 shall apply in relation to such request. 


  

	10.3	 Where a Haleon Group Company is entitled to recover from any other person (other than a Pfizer Group Company or
a Haleon Group Company, but including a Tax Authority) any sum in respect of any matter which has given rise to an obligation of: 


  

	 	(A)	 Pfizer to make a payment under clause 3.1(A); or 



 

	 	(B)	 Pfizer to make a payment under clause 3.1(B), but not of GSK to make a payment under clause
2.1(B), 



  
 31 













 then clause 10.1 and clause 10.2 shall apply mutatis mutandis. 

 

	10.4	 Where a Haleon Group Company is entitled to recover from any other person (other than a GSK Group Company or a
Pfizer Group Company and other than a Haleon Group Company, but including a Tax Authority) any sum in respect of a matter which has given rise to an obligation of GSK and Pfizer to make a payment under clause 2.1(B) and clause 3.1(B)
(respectively), then: 


  

	 	(A)	 GSK and Pfizer shall consult with each other in good faith as to whether to request Haleon to enforce recovery
against the person in question and, if so, what action is required to achieve this. [Where GSK and Pfizer remain unable to agree, the Directing Party shall in good faith take into account and reflect any suggestions or comments from the Non-Directing Party concerning the matter and procure that they are reflected in any action or inaction which is ultimately decided upon to the extent that they are reasonable]; 



 

	 	(B)	 Haleon, if requested by the Directing Party (and subject to GSK and Pfizer indemnifying the relevant Haleon
Group Company on an after-Tax basis against all losses, fines, penalties, interest, charges and Costs which may thereby be incurred (for the purposes of clause 10.11, a “Costs Indemnity”)), take such action as the Directing
Party shall reasonably request in writing, with reasonable notice (taking into account the requirements of clause 10.7 and clause 10.11), to enforce such recovery against the person in question; and 



 

	 	(C)	 Haleon shall procure that the relevant Haleon Group Company shall account to each of GSK and Pfizer
(respectively) for the percentage of the Recovered Amounts corresponding to the proportion of the underlying Haleon Tax Liability that was indemnified by GSK and Pfizer (respectively) under clause 2.1(B) and clause 3.1(B) (and for the
avoidance of doubt taking into account the application of clause 4.10 to clause 4.12 (inclusive)) up to an amount not exceeding (in the case of GSK) the amount paid by GSK under clause 2.1(B) in respect of the relevant
matter or (in the case of Pfizer) the amount paid by Pfizer under clause 3.1(B) in respect of the relevant matter. 


  

	10.5	 The Directing Party must meet its obligations with respect to the
Non-Directing Party as set out in clause 10.4(A) prior to giving any request to Haleon as is mentioned in clause 10.4(B). 



 

	10.6	 GSK and Pfizer shall bear the burden of the indemnity in clause 10.4(B) according to their respective
Relevant Percentages. 


  

	10.7	 If Haleon considers (acting reasonably and in good faith) that any action requested by the Directing Party in
accordance with clause 10.4 has or is likely to have a material and negative impact on the relationship between a Haleon Group Company and a Tax Authority or is or is likely to be materially prejudicial to a Haleon Group Company’s
business, clause 10.11 shall apply in relation to such request. 



  
 32 














	10.8	 Where a GSK Group Company is entitled to recover from any other person (other than a Haleon Group Company and
GSK Group Company, but including a Tax Authority) any sum in respect of any matter to which clause 5.1 relates, GSK shall procure that the relevant GSK Group Company shall (if requested by and subject to Haleon indemnifying and securing the
relevant GSK Group Company on an after-Tax basis against all losses, fines, penalties, interest, charges and Costs which may thereby be incurred (for the purposes of clause 10.11, a “Costs
Indemnity”)) take such action as Haleon shall reasonably request in writing, with reasonable notice (taking into account the requirements of clause 10.9 and clause 10.11), to enforce such recovery against the person in
question and GSK shall procure that the relevant GSK Group Company shall account to Haleon for any Recovered Amounts, up to an amount not exceeding the amount paid by Haleon under clause 5.1 in respect of the relevant matter.



  

	10.9	 If GSK considers (acting reasonably and in good faith) that any action requested by Haleon in accordance with
clause 10.8 has or is likely to have a material and negative impact on the relationship between a GSK Group Company and a Tax Authority, or is likely to be materially prejudicial to a GSK Group Company’s business, clause
10.11 shall apply in relation to such request. 


  

	10.10	 Where a Pfizer Group Company is entitled to recover from any other person (other than a Haleon Group Company or
a Pfizer Group Company, but including a Tax Authority) any sum in respect of any matter to which clause 5.3 relates, then clause 10.8 and clause 10.9 shall apply mutatis mutandis. 



 

	10.11	 Clause 12.19 shall apply mutatis mutandis for the purposes of clause 10.2, clause
10.7 and clause 10.9 (including as such clauses are applied mutatis mutandis for the purposes of clause 10.3 and clause 10.10) if this clause 10.11 applies and: 



 

	 	(A)	 if the Affected Party agrees to give effect to the requested relevant action in accordance with clause
12.19(A), then for the avoidance of doubt the relevant Costs Indemnity shall apply in accordance with its terms in respect of any losses, fines, penalties, interest, charges and Costs arising as a result of such request; and



  

	 	(B)	 if the Affected Party declines to give effect to the requested relevant action in accordance with clause
12.19(B), an amount equal to what would reasonably be expected to have been the applicable Recovered Amount (but for the Affected Party exercising its rights under clause 12.19(B), as applied mutatis mutandis under this clause
10.11) shall still be treated as a “Recovered Amount” to which the Requesting Party is entitled under clause 10.1, clause 10.4 or clause 10.8 (as applicable). 



 

	10.12	 In this clause 10 only, “Recovered Amount” means: 



 

	 	(A)	 sums recovered (including any interest paid by a person from whom the recovery is made) less any Costs of
recovery and any Tax chargeable thereon suffered by the person making the recovery; and 


  

	 	(B)	 any amounts deemed to be Recovered Amounts under clause 10.2, clause 10.7 and clause 10.9
(including, where relevant, as any such clauses apply when read together with clause 10.3 or clause 10.10). 


  

	11.	 Reliefs 


  

	11.1	 Where GSK has made a payment to Haleon under clause 2.1 in respect of a Haleon Tax Liability, or such a
payment has become due, and such Haleon Tax Liability gives rise to (or the circumstances giving rise thereto give rise to) a Relief that either (i) comprises a repayment of Tax to or (ii) results in an actual saving of Tax for a Haleon
Group Company which (in either case) otherwise would not have arisen, Haleon shall procure that the amount of the repayment or cash tax saving less any Costs of recovery and any Tax thereon (the “Relevant Amount”) shall be dealt
with in accordance with clause 11.2. 


  

	11.2	 Subject to clause 11.4, the Relevant Amount: 



 

	 	(A)	 shall first be set off against any payment then due from GSK under this Deed; 



  
 33 














	 	(B)	 to the extent there is an excess, a refund shall be made to GSK of any previous payment or payments made by GSK
under this Deed and not previously refunded under this clause 11.2(B) up to the amount of such excess; and 


  

	 	(C)	 to the extent that the excess referred to in clause 11.2(B) is not exhausted under that clause, then the
remainder of that excess shall be carried forward and set off against any future payment or payments which become due from GSK under this Deed. 


  

	11.3	 The provisions of clause 11.1 and clause 11.2 above shall (subject to clause 11.4) apply,
mutatis mutandis, to the Parties in relation to: 


  

	 	(A)	 any Haleon Tax Liability which has resulted in a payment having been made or becoming due from Pfizer under
clause 3.1; and 


  

	 	(B)	 any GSK Tax Liability which has resulted in a payment having been made or becoming due from Haleon under
clause 5.1; and 


  

	 	(C)	 any Pfizer Tax Liability which has resulted in a payment having been made or becoming due from Haleon under
clause 5.3. 


  

	11.4	 Where both GSK and Pfizer have made a payment under clause 2.1(B) and clause 3.1(B) in respect of
a particular Haleon Tax Liability, or such payment has become due, and clause 11.1 applies (including as it applies by virtue of clause 11.3(A)), the percentage of the Relevant Amount corresponding to the proportion of the underlying
Haleon Tax Liability for which GSK and Pfizer (respectively) was or would be liable for under clause 2.1(B) and clause 3.1(B) (and for the avoidance of doubt taking into account the application of clause 4.10 to clause
4.12 (inclusive)) shall be applied for GSK’s and Pfizer’s benefit (respectively) as specified in clause 11.2 (including as it applies by virtue of clause 11.3(A)). 



 

	12.	 Conduct of Tax Authority Claims 



Notification of Tax Authority Claim 
  

	12.1	 If a Haleon Group Company becomes aware of any Tax Authority Claim relating to its Tax affairs which is
relevant for the purposes of clause 2 or clause 3 (or any circumstances likely to give rise to such a Tax Authority Claim), Haleon shall give written notice thereof to both GSK and Pfizer as soon as reasonably practicable and in any
event within 10 Business Days, provided that the right to indemnification pursuant to clause 2 or clause 3 shall not be limited for failure to notify except to the extent that such failure actually prejudices or increases the relevant
Tax Liability. 


  

	12.2	 If a GSK Group Company or Pfizer Group Company becomes aware of any Tax Authority Claim relating to its Tax
affairs which is relevant for the purposes of clause 5.1 or clause 5.3 respectively (or if a GSK Group Company or Pfizer Group Company becomes aware of any circumstances likely to give rise to such a Tax Authority Claim), GSK or Pfizer
(as applicable) shall give written notice thereof to Haleon as soon as reasonably practicable 



  
 34 














	 	
and in any event within 10 Business Days, provided that the right to indemnification pursuant to clause 5.1 or clause 5.3 shall not be limited for failure to notify except to the
extent that such failure actually prejudices or increases the relevant Tax Liability. 

 Tax Authority Claims relating to a matter for
which GSK may be liable 
  

	12.3	 In relation to any Tax Authority Claim in respect of a potential Haleon Tax Liability which, if it becomes an
actual Haleon Tax Liability, is reasonably expected to give rise to an obligation of: 


  

	 	(A)	 GSK to make a payment under clause 2.1(A); or 



 

	 	(B)	 GSK to make a payment under clause 2.1(B), but not of Pfizer to make a payment under clause
3.1(B), 


 then, provided that GSK shall indemnify the relevant Haleon Group Company on an after-Tax basis against any losses, fines, penalties, interest, charges, and Costs arising therefrom, (for the purposes of clause 12.19, a “Costs Indemnity”), Haleon shall (subject to
clause 12.5) procure that the relevant Haleon Group Company shall take such action as GSK may reasonably request, with reasonable notice (taking into account the requirements of clause 12.5 and clause 12.19), to avoid, dispute,
resist, appeal, compromise or defend such Tax Authority Claim, provided that the relevant Haleon Group Company shall not be required to settle any such Tax Authority Claim if doing so would reasonably be expected to materially increase the Tax
liabilities of the Haleon Group Companies (taking into account any indemnification for the same under this Deed, any Transaction Document, the Cosmos SAPA and the Constellation Tax Covenant) without Haleon’s prior written consent, such consent
not to be unreasonably withheld, delayed or conditioned. GSK shall have the right to nominate professional advisers for this purpose provided always that the appointment of solicitors or other professional advisers shall be subject to the approval
of the relevant Haleon Group Company (such approval not to be unreasonably withheld or delayed). 
  

	12.4	 To enable full exercise and performance of the rights and obligations in clause 12.3:



  

	 	(A)	 Haleon shall keep GSK fully informed of all matters pertaining to the Tax Authority Claim mentioned in
clause 12.3 (and vice versa); 


  

	 	(B)	 Haleon shall provide GSK with copies of all correspondence and material documents pertaining to the Tax
Authority Claim mentioned in clause 12.3 (and vice versa); 


  

	 	(C)	 written communications (including any emails) and any material documents pertaining to the Tax Authority Claim
which Haleon (or the relevant Haleon Group Company) intends to transmit to the relevant Tax Authority shall first be submitted in good time by Haleon to GSK for review. Haleon shall (or shall procure that) any reasonable written comments timely
received from GSK shall (subject to clause 12.5 and clause 12.19) be reflected in such written communications and (where applicable) documents; and 


  

	 	(D)	 to the extent permitted by applicable Law, a representative from each of Haleon and GSK (and their respective
nominated advisors) shall be given the opportunity 



  
 35 














	 	
to attend any meeting or call with any Tax Authority pertaining to the Tax Authority Claim and shall be fully briefed in relation to the purposes of that meeting or call in sufficient time to
enable the representative or advisor to prepare for it. 

  

	12.5	 If Haleon considers (acting reasonably and in good faith) that the exercise by GSK of its Conduct Rights in
relation to any such Tax Authority Claim as is mentioned in clause 12.3 and/or clause 12.4(C) has or is likely to have a material and negative impact on the relationship between a Haleon Group Company and a Tax Authority [or is or is likely
to be materially prejudicial to a Haleon Group Company’s business, clause 12.19 shall apply in relation to such exercise. 


  

	12.6	 For the avoidance of doubt, nothing in clause 12.3 or clause 12.4 shall require any Haleon Group
Company to give any communication or submit any document to a Tax Authority that is not, to the best of that Haleon Group Company’s knowledge, correct and complete. 



Tax Authority Claims relating to a matter for which Pfizer may be liable 
  

	12.7	 In relation to any Tax Authority Claim in respect of a potential Haleon Tax Liability which, if it becomes an
actual Haleon Tax Liability, is reasonably expected to give rise to an obligation: 


  

	 	(A)	 Pfizer to make a payment of clause 3.1(A); or 



 

	 	(B)	 Pfizer to make a payment under clause 3.1(B), but not of GSK to make a payment under clause
2.1(B), 


 then clause 12.3 to clause 12.6 (inclusive) shall apply mutatis mutandis. 

Tax Authority Claims relating to a matter for which both GSK and Pfizer may be liable 

 

	12.8	 In relation to any Tax Authority Claim in respect of a potential Haleon Tax Liability which, if it becomes an
actual Haleon Tax Liability, is reasonably expected to give rise to an obligation of GSK and Pfizer to make a payment under clause 2.1(B) and clause 3.1(B) (respectively), then: 



 

	 	(A)	 GSK and Pfizer shall consult with each other in good faith as to whether Haleon should take action to avoid,
dispute, resist, appeal, compromise or defend the Tax Authority Claim in question and, if so, what that action should be (including whether, and if so which, professional advisers should be engaged). Where GSK and Pfizer remain unable to agree, the
Directing Party shall in good faith take into account and reflect any suggestions or comments from the Non-Directing Party concerning the matter and procure that they are reflected in any action or inaction
which is ultimately decided upon to the extent that they are reasonable; and 


  

	 	(B)	 provided that GSK and Pfizer shall indemnify the relevant Haleon Group Company on an after-Tax basis against any losses, fines, penalties, interest, charges, and Costs arising therefrom (for the purposes of clause 12.19, a “Costs Indemnity”), Haleon shall (subject to clause
12.11) 



  
 36 














	 	
procure that the relevant Haleon Group Company shall take such action as the Directing Party may reasonably request, with reasonable notice (taking into account the requirements of clause 12.11
and clause 12.19), to avoid, dispute, resist, appeal, compromise or defend such Tax Authority Claim, provided that the relevant Haleon Group Company shall not be required to settle any such Tax Authority Claim if doing so would reasonably be
expected to materially increase the Tax liabilities of the Haleon Group Companies (taking into account any indemnification for the same under this Deed, any Transaction Document, the Cosmos SAPA and the Constellation Tax Covenant) without
Haleon’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. The Directing Party shall have the right to nominate professional advisers for this purpose provided always that the appointment of solicitors
or other professional advisers shall be subject to the approval of the relevant Haleon Group Company (such approval not to be unreasonably withheld or delayed). 

  

	12.9	 To enable full exercise and performance of the rights and obligations in clause 12.8:



  

	 	(A)	 Haleon shall keep GSK and Pfizer fully informed of all matters pertaining to the potential Haleon Tax Liability
mentioned in clause 12.8 (and vice versa); 


  

	 	(B)	 Haleon shall provide GSK and Pfizer with copies of all correspondence and material documents pertaining to the
Tax Authority Claim mentioned in clause 12.8 (and vice versa); 


  

	 	(C)	 written communications (including any emails) and any material documents pertaining to the Tax Authority Claim
which Haleon (or the relevant Haleon Group Company) intends to transmit to the relevant Tax Authority shall first be submitted in good time by Haleon to GSK and to Pfizer for review. Haleon shall (or shall procure that) any reasonable written
comments timely received from the Directing Party shall (subject to clause 12.11 and clause 12.19) be reflected in such written communications and (where applicable) documents; and 



 

	 	(D)	 to the extent permitted by applicable Law, a representative from each of Haleon, GSK and Pfizer (and their
respective nominated advisors) shall be given the opportunity to attend any meeting or call with any Tax Authority pertaining to the Tax Authority Claim and shall be fully briefed in relation to the purposes of that meeting or call in sufficient
time to enable the representative or advisor to prepare for it. 


  

	12.10	 The Directing Party must meet its obligations with respect to the
Non-Directing Party as set out in clause 12.8(A) prior to giving any request or comments to Haleon as mentioned in clause 12.8 and clause 12.9. 



 

	12.11	 If Haleon considers (acting reasonably and in good faith) that the exercise by GSK or Pfizer of their
respective Conduct Rights in relation to any such Tax Authority Claim as is mentioned in clause 12.8 and/or clause 12.9(C) has or is likely to have a material and negative impact on the relationship between a Haleon Group Company and a Tax
Authority [or is likely to be materially prejudicial to a Haleon Group Company’s business, clause 12.19 shall apply in relation to such exercise. 



  
 37 














	12.12	 For the avoidance of doubt, nothing in clause 12.8 or clause 12.9 shall require any Haleon Group
Company to give any communication or submit any document to a Tax Authority that is not, to the best of that Haleon Group Company’s knowledge, correct and complete. 



 

	12.13	 [GSK and Pfizer shall each bear the burden of the indemnity in clause 12.8 according to the proportion
of the underlying Haleon Tax Liability that would be payable by GSK or Pfizer respectively if it were to become an actual Haleon Tax Liability in respect of the relevant matter under clause 2.1(B) and clause 3.1(B) (and for the avoidance of doubt
taking into account the application of clause 4.10 to clause 4.12 (inclusive))]. 


 Tax Authority Claims relating to a matter for which
Haleon may be liable 
  

	12.14	 In relation to any potential GSK Tax Liability which if it becomes an actual GSK Tax Liability, is reasonably
expected to give rise to an obligation of Haleon for the purposes of clause 5.1, then provided that Haleon shall indemnify the relevant GSK Group Company on an after-Tax basis against any losses, fines,
penalties, interest, charges, and Costs arising therefrom, (for the purposes of clause 12.19, a “Costs Indemnity”), GSK shall (subject to clause 12.5) procure that the relevant GSK Group Company shall take such action
as GSK may reasonably request, with reasonable notice (taking into account the requirements of clause 12.16 and clause 12.19), avoid, dispute, resist, appeal, compromise or defend such Tax Authority Claim, provided that the relevant
GSK Group Company shall not be required to settle any such Tax Authority Claim if doing so would reasonably be expected to materially increase the Tax liabilities of the GSK Group Companies (taking into account any indemnification for the same under
this Deed, any Transaction Document or the Cosmos SAPA) without GSK’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. Haleon shall have the right to nominate professional advisers for this purpose
provided always that the appointment of solicitors or other professional advisers shall be subject to the approval of the relevant GSK Group Company (such approval not to be unreasonably withheld or delayed). 



 

	12.15	 To enable full exercise and performance of the rights and obligations in clause 12.14:



  

	 	(A)	 GSK shall keep Haleon fully informed of all matters pertaining to the Tax Authority Claim mentioned in
clause 12.14 (and vice versa); 


  

	 	(B)	 GSK shall provide Haleon with copies of all correspondence and material documents pertaining to the Tax
Authority Claim mentioned in clause 12.14 (and vice versa); 


  

	 	(C)	 written communications (including any emails) and any material documents pertaining to the Tax Authority Claim
which GSK (or the relevant GSK Group Company) intends to transmit to the relevant Tax Authority shall first be submitted in good time by GSK to Haleon for review. GSK shall (or shall procure that) any reasonable written comments timely received from
Haleon shall (subject to clause 12.16 and clause 12.19) be reflected in such written communications and (where applicable) documents; and 



  
 38 














	 	(D)	 to the extent permitted by applicable Law, a representative from each of GSK and Haleon (and their respective
nominated advisors) shall be given the opportunity to attend any meeting or call with any Tax Authority pertaining to the Tax Authority Claim and shall be fully briefed in relation to the purposes of that meeting or call in sufficient time to enable
the representative or advisor to prepare for it. 


  

	12.16	 If GSK considers (acting reasonably and in good faith) that the exercise by Haleon of its Conduct Rights in
relation to any Tax Authority Claim as mentioned in clause 12.14 and/or clause 12.15(C) has or is likely to have a material and negative impact on the relationship between a GSK Group Company and a Tax Authority or is or is likely to
be materially prejudicial to a GSK Group Company’s business, clause 12.19 shall apply in relation to such exercise. 


  

	12.17	 For the avoidance of doubt, nothing in clause 12.14 or clause 12.15 shall require any GSK Group
Company to give any communication or submit any document to a Tax Authority that is not, to the best of that GSK Group Company’s knowledge, correct and complete. 



 

	12.18	 In relation to any Tax Authority Claim in respect of a potential Pfizer Tax Liability which if it becomes an
actual Pfizer Tax Liability, is reasonably expected to give rise to an obligation of Haleon for the purposes of clause 5.3, clause 12.14 to clause 12.17 (inclusive) shall apply mutatis mutandis. 



 

	12.19	 For the purposes of clause 12.5, clause 12.11 and clause 12.16, including as such clauses
are applied mutatis mutandis for the purposes clause 12.7 and clause 12.18, if this clause 12.19 applies the Party whose Group member is or is likely to be impacted or prejudicially affected by the relevant exercise of
Conduct Rights (for the purposes of this clause 12.19, the “Affected Party”) shall notify in writing the Party or Parties whose exercise of Conduct Rights is causing or is likely to cause the relevant impact or prejudicial effect
(for the purposes of this clause 12.19, each, an “Exercising Party”) of the application of this clause 12.19, and the Affected Party and each Exercising Party shall, promptly following such notification and in any event prior
to the deadline for the requested action to be taken, discuss in good faith the reasonableness in all the circumstances of each Exercising Party exercising its Conduct Rights in relation to the relevant Tax Authority Claim in such manner, with such
discussion taking into account as relevant circumstances both the extent of the actual and likely Tax and non-Tax impact or prejudicial effect on the relevant Affected Party’s Group member of each
Exercising Party so exercising its Conduct Rights and the extent to which any such impact or prejudicial effect on the Affected Party is indemnified by an Exercising Party (or otherwise). Following such a discussion, if an Exercising Party wishes to
continue to exercise its Conduct Rights in relation to the relevant matter in a way that has or is likely to have a material and negative impact on the relationship between the Affected Party and a Tax Authority or is or is likely to be materially
prejudicial to the Affected Party’s business: 


  

	 	(A)	 if the Affected Party agrees to give effect to such exercise by each Exercising Party of its Conduct Rights,
for the avoidance of doubt the relevant Costs Indemnity shall apply in accordance with its terms in respect of any losses, fines, penalties, interest, charges and Costs arising as a result of such exercise; or 



 

	 	(B)	 the Affected Party shall be entitled to decline to give effect to those Conduct Rights provided always that if
the Affected Party declines to give effect to those Conduct Rights pursuant to this clause 12.19(B), each Exercising Party shall not be liable under this Deed in respect of the matter to which the Tax Authority Claim in question relates.



 Definition of “Conduct Rights” for purposes of this clause 12 

 

	12.20	 For the purposes of this clause 12 only, “Conduct Rights” shall mean:



  

	 	(A)	 in clause 12.5, those rights in relation to a Tax Authority Claim as are set out in clause 12.3
and clause 12.4 (including as such clauses apply when read together with clause 12.7); 


  

	 	(B)	 in clause 12.11, those rights in relation to a Tax Authority Claim as are set out in clause 12.8
and clause 12.9; and 


  

	 	(C)	 in relation to clause 12.16, those rights in relation to a Tax Authority Claim as are set out in
clause 12.14 and clause 12.15 (including as such clauses apply when read together with clause 12.18). 


  

	13.	 Tax Returns 


  

	13.1	 This clause 13 shall be subject in all respects to the Cosmos SAPA. Where there is any inconsistency
between the provisions of this clause 13 and the Cosmos SAPA (as amended by clause 17), the Cosmos SAPA (as so amended) shall prevail. 


  

	13.2	 Where there is conflict between the provisions of this clause 13 and the provisions of clause 12,
clause 12 shall take precedence. 



  
 39 













 Responsibility for preparation of Tax Returns 

 

	13.3	 Haleon shall prepare (or shall procure that there is prepared) the Tax Returns for all members of the Haleon
Group for all Tax Periods (including, for the avoidance of doubt, the Tax Returns of GSKCHHL for any Straddle Periods), excluding any: 


  

	 	(A)	 US State Joint Tax Returns; 



 

	 	(B)	 Tax Returns for PFCHHL for any Straddle Period; and 



 

	 	(C)	 any Tax Returns the preparation of which GSK is responsible for pursuant to clause 15.2 (if any).



  

	13.4	 GSK shall prepare (or shall procure that there is prepared): 



 

	 	(A)	 the Tax Returns for all members of the GSK Group for all Tax Periods (excluding any Tax Returns the preparation
of which Haleon is responsible for pursuant to clause 15.2 (if any)); and 


  

	 	(B)	 any US State Joint Tax Returns. 



 

	13.5	 Pfizer shall prepare (or shall procure that there is prepared): 



 

	 	(A)	 the Tax Returns for all members of the Pfizer Group for all Tax Periods; and 



 

	 	(B)	 the Tax Returns for PFCHHL for any Straddle Period. 



 

	13.6	 Pfizer shall continue to act as the Partnership Representative (as defined in the Cosmos SCA) for all Tax
Periods of JVCo that begin prior to Completion and, in its capacity as such, shall have all rights and obligations that it would have under the Cosmos SCA (had it remained in effect and had references to “GSK” and “GSK’s
Group” therein been references to “Haleon” and “Haleon Group”). 


 Right to review and comment (Tax Returns
prepared by Haleon) 
  

	13.7	 Haleon shall: 


  

	 	(A)	 submit to GSK: 


  

	 	(i)	 each Tax Return of GSKCHHL for any Straddle Period; and 



 

	 	(ii)	 each such Tax Return referred to in clause 13.3 as relates to a matter for which GSK would reasonably be
expected to be liable to Haleon under clause 2.1; and 


  

	 	(B)	 submit to Pfizer each such Tax Return referred to in clause 13.3 as relates to a matter for which Pfizer
would reasonably be expected to be liable to Haleon under clause 3.1, 



  
 40 













 in draft form at least 15 days before the applicable Filing Date (or, in the case of an
Income Tax Return, at least 30 days before that Filing Date). 
  

	13.8	 Haleon shall give GSK and/or Pfizer (as the case may be) an opportunity to make comments on the applicable Tax
Returns as mentioned in clause 13.7. Haleon shall procure that all reasonable written comments of GSK which relate to any matter for which a GSK Group Company may be liable, and/or (as applicable) all reasonable written comments of Pfizer
which relate to any matter for which a Pfizer Group Company may be liable, that are (in either case) received at least 5 days before the Filing Date (or, in the case of an Income Tax Return, at least 15 days before the Filing Date) are properly
reflected in the relevant Tax Return and that Tax Return is submitted on a timely basis to the appropriate Tax Authority; provided that Haleon shall not be obliged to procure that a Haleon Group Company takes any such action as is mentioned in this
clause 13.8 in relation to a Tax Return that is not, to the best of that Haleon Group Company’s knowledge, correct and complete. 


  

	13.9	 In the event that the comments of Haleon, GSK and Pfizer with regard to any Tax Return as is mentioned in
clause 13.7 conflict, the affected Parties shall consult with each other in good faith to attempt to reach a common view. If such agreement cannot be reached, the comments of the Party which (together with its Group) would reasonably expect
to bear the greater burden of the Tax in relation to the matter in question (including, for the avoidance of doubt, as a result of the indemnification provisions in this Deed) shall prevail; provided that Haleon shall not be obliged to procure that
a Haleon Group Company takes any such action as is mentioned in this clause 13.9 in relation to a Tax Return that is not, to the best of that member’s knowledge, correct and complete. 



Right to review and comment (Tax Returns prepared by GSK) 
  

	13.10	 GSK shall submit to Haleon: 



 

	 	(A)	 each such Tax Return referred to in clause 13.4(A) as relates to a matter for which Haleon would
reasonably be expected to be liable to GSK under clause 5.1 in draft form at least 15 days before the applicable Filing Date (or, in the case of an Income Tax Return, at least 30 days before that Filing Date); and 



 

	 	(B)	 each such Tax Return referred to in clause 13.4(B) at least 5 Business Days before the applicable Filing
Date. 


  

	13.11	 GSK shall give Haleon an opportunity to make comments on the Tax Returns as mentioned in clause 13.10.
GSK shall procure that all reasonable written comments of Haleon which relate to any matter for which a Haleon Group Company may be liable received at least 5 days before the Filing Date (or, in the case of an Income Tax Return, at least 15 days
before the Filing Date or, in the case of a US State Joint Tax Return, at least 2 Business Days before the Filing Date) are properly reflected in the relevant Tax Return and that Tax Return is submitted on a timely basis to the appropriate Tax
Authority; provided that GSK shall not be obliged to procure that a GSK Group Company takes any such action as is mentioned in this clause 13.11 in relation to a Tax Return that is not, to the best of that GSK Group Company’s knowledge,
correct and complete. 



  
 41 













 Right to review and comment (Tax Returns prepared by Pfizer) 

 

	13.12	 Where a Tax Return of a member of the Pfizer Group relates to a matter for which Haleon would reasonably be
expected to be liable to Pfizer under clause 5.3, Pfizer shall provide Haleon with a written summary of such matters in such detail as is reasonable in the circumstances (including, without limitation, an explanation as to how they are
reflected in the applicable Tax Return), at least 15 days before the applicable Filing Date (or, in the case of an Income Tax Return, at least 30 days before that Filing Date). 



 

	13.13	 Pfizer shall give Haleon an opportunity to make comments on the approach to be taken in the Tax Returns to the
matters mentioned in clause 13.12. Pfizer shall procure that all reasonable written comments of Haleon which relate to any matter for which a Haleon Group Company may be liable received at least 5 days before the Filing Date (or, in the
case of an Income Tax Return, at least 15 days before the Filing Date) are properly reflected in the relevant Tax Return and that Tax Return is submitted on a timely basis to the appropriate Tax Authority; provided that Pfizer shall not be obliged
to procure that a Pfizer Group Company takes any such action as is mentioned in clause 13.13 in relation to a Tax Return that is not, to the best of that Pfizer Group Company’s knowledge, correct and complete. 



General 
  

	13.14	 Subject to clause 13.15, each of GSK and Pfizer agrees that within any applicable time limits they shall make a
joint notification (or notifications) to the relevant Tax Authority or Tax Authorities regarding the Indirect CGT treatment of certain of the steps comprising the Separation Transaction and the Reorganisation (“Indirect CGT
Reporting”) and shall cooperate in good faith in respect of any related matters, in each case in accordance with Schedule 3. 


  

	13.15	 Each of GSK, Pfizer and Haleon shall (and shall procure, respectively, that the GSK Group Companies, Pfizer
Group Companies and Haleon Group Companies shall) on reasonable written request, afford such access to their books, accounts and records (including any copies of legal or tax advice sought from third party advisers) and such other assistance as is
proportionate and reasonably required to enable each other Party to exercise its rights and fulfil its obligations under this clause 13 or clause 15.2 (including, for the avoidance of doubt, information necessary to prepare and file
Forms 5471 and/or 



  
 42 














	 	
to compute any required inclusions under Section 951(a) or 951A(a) or the passive foreign investment company (“PFIC”) rules of Sections 1291 to 1298, and including in connection
with any Tax Authority Claim) provided that no party shall be required to provide information or documents if such action could reasonably be expected to result in the waiver of privilege (and such waiver cannot be avoided via outside Counsel to
outside Counsel information sharing) or to be commercially detrimental. Each of GSK, Pfizer and Haleon shall use all reasonable endeavours to ensure such access is provided within 10 Business Days from receipt of a written request. Notwithstanding
anything else in this provision to the contrary, (i) each of the Parties is responsible for its own Tax reporting, (ii) the Haleon Group shall not be required to maintain its accounts according to U.S. Tax accounting principles; and
(iii) any information provided to a Party pursuant to clause 13.15 shall be used solely for income and franchise Tax, and financial reporting purposes and will not be disclosed to any person for any other purpose. 


 

	13.16	 Where one Party (the “Requesting Party”) makes any requests of another Party (the
“Requested Party”) under clause 13.15, the first £150,000 of Costs to meet those requests as are incurred in any one calendar year shall be borne by the Requested Party, with the Requesting Party bearing any Cost in
excess of such amount, provided that any costs incurred by a Haleon Group Company as provided for in clause 9.4 of the Cosmos SHA (including as the provisions in such clause continue pursuant to Schedule 2 of the SCIA) or clause 11.11 of the Cosmos
SCA in the relevant period shall be counted towards the amount borne by Haleon as Requested Party for that period for the purposes of this clause 13.16 (and vice versa).



 

	13.17	 Each of GSK, Pfizer and Haleon shall (and shall procure, respectively, that the GSK Group Companies, Pfizer
Group Companies and Haleon Group Companies shall) retain, for at least 6 years from Demerger Completion, such books, accounts and records (including any copies of legal or tax advice sought from third party advisers) as might reasonably be expected
to be required by each other Party or any member of their Group (in each case) to ascertain its Tax position or that might reasonably be required for any of the purposes referred to in clause 13.13. 



 

	13.18	 Nothing done by or at the request of Haleon pursuant to this clause 13 shall in any respect restrict or
reduce any rights that: 


  

	 	(A)	 GSK may have to make a claim against Haleon under this Deed in respect of any such GSK Tax Liability as is
mentioned in clause 5.1; or 


  

	 	(B)	 Pfizer may have to make a claim against Haleon under this Deed in respect of any such Pfizer Tax Liability as
is mentioned in clause 5.3. 


  

	13.19	 Nothing done by or at the request of GSK or Pfizer pursuant to this clause 13 shall in any respect
restrict or reduce any rights that Haleon may have to make a claim against GSK under clause 2 or Pfizer under clause 3. 


  

	13.20	 If a GSK Group Company or Pfizer Group Company comes into possession of any notice, letter or other document
(by or on behalf of any Tax Authority or otherwise) which is addressed to, or otherwise solely relates to the Tax affairs of a Haleon Group Company, GSK or Pfizer (as applicable) shall, or shall procure, that such notice, letter or document is sent
as soon as practicably possible to the relevant Haleon Group Company. 


  

	13.21	 If a Haleon Group Company comes into possession of any notice, letter or other document (by or on behalf of any
Tax Authority or otherwise) which is addressed to, or 



  
 43 














	 	
otherwise solely relates to the Tax affairs of a GSK Group Company or a Pfizer Group Company, Haleon shall, or shall procure, that such notice, letter or document is sent as soon as practicably
possible to the relevant GSK Group Company or Pfizer Group Company. 

  

	13.22	 The Parties agree and acknowledge that notwithstanding clause 14.1 of the Cosmos SCA, the provisions of clause
11.11 of the Cosmos SCA shall not continue after termination of the Cosmos SCA and, instead, this clause 13 shall apply. 


 No
extension of Tax Authority time limits 
  

	13.23	 Haleon shall not, and shall procure that each Haleon Group Company shall not, agree with any Tax Authority to
waive or extend any Relevant Time Limit if such action concerns any Purchaser Parent Indemnified Taxes (as defined in the Cosmos SAPA) or any Tax for which GSK may be liable under this Deed without GSK’s prior written consent (such consent not
with be unreasonably withheld or delayed). 


  

	13.24	 Haleon shall not, and shall procure that each Haleon Group Company shall not, agree with any Tax Authority to
waive or extend any Relevant Time Limit if such action concerns any Seller Indemnified Taxes (as defined in the Cosmos SAPA) or any Tax for which Pfizer may be liable under this Deed without Pfizer’s prior written consent (such consent not with
be unreasonably withheld or delayed). 


 Disclaimer of elections 

 

	13.25	 GSK shall procure that (except where requested in writing by Haleon or required by Law) after Demerger
Completion no GSK Group Company: 


  

	 	(A)	 amends, withdraws or disclaims any election or claim made before Demerger Completion; or 



 

	 	(B)	 disclaims any allowance or Relief claimed before Demerger Completion, 



in each case, which is reasonably likely to affect the liability to, or the right to repayment of, Tax of a Haleon Group Company. 

 

	13.26	 Pfizer shall procure that (except where requested in writing by Haleon or required by Law) after Demerger
Completion no Pfizer Group Company: 


  

	 	(A)	 amends, withdraws or disclaims any election or claim made before Demerger Completion; or 



 

	 	(B)	 disclaims any allowance or Relief claimed before Demerger Completion, 



in each case, which is reasonably likely to affect the liability to, or the right to repayment of, Tax of a Haleon Group Company. 

  
 44 














	13.27	 Haleon shall procure that (except where requested in writing by GSK or required by Law) after Demerger
Completion no Haleon Group Company: 


  

	 	(A)	 amends, withdraws or disclaims any election or claim made before Demerger Completion; or 



 

	 	(B)	 disclaims any allowance or Relief claimed before Demerger Completion, 



in each case, which is reasonably likely to affect the liability to, or the right to repayment of, Tax of a GSK Group Company. 

 

	13.28	 Haleon shall procure that (except where requested in writing by Pfizer or required by Law) after Demerger
Completion no Haleon Group Company: 


  

	 	(A)	 amends, withdraws or disclaims any election or claim made before Demerger Completion; or 




	 	


	 	(B)	 disclaims any allowance or Relief claimed before Demerger Completion, 



in each case, which is reasonably likely to affect the liability to, or the right to repayment of, Tax of a Pfizer Group Company. 

 

	14.	 Transfer Pricing 



 

	14.1	 This clause 14 shall not apply in respect of a liability to Tax as a result of a Transfer Pricing
Adjustment to the extent that the same falls within any of the circumstances mentioned in clause 4.1(L) or to the extent that any rights or liabilities in respect of the same have accrued under Clause 6 (Transfer Pricing) of the Cosmos SCA.



  

	14.2	 If and to the extent that GSK (or any person connected with GSK) or Pfizer (or any person connected with
Pfizer) has or may have an increased liability to Tax as a result of a Transfer Pricing Adjustment in respect of which Haleon or any member of Haleon’s Group is able to claim a Compensating Adjustment, then: 



 

	 	(A)	 Haleon shall, or shall procure that the relevant member of Haleon’s Group shall, if GSK or Pfizer (as the
case may be) so requests, use reasonable commercial efforts to claim the Compensating Adjustment; and 


  

	 	(B)	 if Haleon (or the relevant member of Haleon’s Group) receives or obtains a payment or other Relief which
comprises or would not have arisen but for such Compensating Adjustment, then (as applicable) the amount of the payment received or the amount that the person concerned will save by virtue of the Relief (less any Costs of recovering or obtaining
such payment or other Relief and any Tax actually suffered thereon) shall be paid by Haleon (or the relevant member of Haleon’s Group) by way of Balancing Payment to GSK (or the relevant person connected with GSK) or Pfizer (or the relevant
person connected with Pfizer), as the case may be. 



  
 45 














	14.3	 If and to the extent that Haleon (or any person connected with Haleon) has or may have an increased liability
to Tax as a result of a Transfer Pricing Adjustment in respect of which GSK (or any member of GSK’s Group) or Pfizer (or any member of Pfizer’s Group) is able to claim a Compensating Adjustment, then: 



 

	 	(A)	 as applicable, GSK shall (or shall procure that the relevant member of GSK’s Group shall) or Pfizer shall
(or shall procure that the relevant member of GSK’s Group shall), if Haleon so requests, use reasonable commercial efforts to claim the Compensating Adjustment; and 



 

	 	(B)	 if, as applicable, GSK (or a member of the GSK Group) or Pfizer (or a member of the Pfizer Group) receives or
obtains a payment or other Relief which comprises or would not have arisen but for such Compensating Adjustment, then the lesser of the amount received or the amount that the person concerned will save by virtue of the payment or other Relief (less
any Costs of recovering or obtaining such payment or other Relief and any Tax actually suffered thereon) shall be paid by, as applicable, GSK (or the relevant member of GSK’s Group) or Pfizer (or the relevant member of Pfizer’s Group) by
way of Balancing Payment to Haleon (or the relevant person connected with Haleon). 


  

	14.4	 A Balancing Payment to be made under clause 14.2 or clause 14.3 shall be made within 10
Business Days from the date on which notice setting out the amount due is received by the person that would be liable to make the Balancing Payment under clause 14.1 or clause 14.3 as applicable, or (if later): 



 

	 	(A)	 in a case where the Relief referred to in clause 14.2(B) or clause 14.3(B) (as applicable) is a
right to repayment of any Tax, 10 Business Days after such repayment is received; and 


  

	 	(B)	 in a case where the Relief referred to in clause 14.2(B) or clause 14.3(B) (as applicable) is not
a right to repayment of any Tax, the date which is 10 Business Days prior to the last day on which the person claiming the Compensating Adjustment would have been due to make an actual payment of Tax had it not been for such Relief.



  

	14.5	 In this clause 14 only, a person is “connected” with another person if they are
connected with that other person for the purposes of the transfer pricing legislation in force in the territory in which a Transfer Pricing Adjustment is imposed, provided that Haleon and the Haleon Group shall be deemed not to be
“connected” with either GSK or Pfizer. 


  

	15.	 Tax Consolidations 



 

	15.1	 To the extent that the same has not been done before Demerger Completion, GSK and Haleon shall (and shall
procure that the members of their respective Groups shall) procure that any Haleon Group Company be removed from any GSK Tax Consolidation and any GSK Group Company be removed from any Haleon Tax Consolidation, with effect from, to the extent
permitted by applicable Law, no later than Demerger Completion. GSK and Haleon shall co-operate with each other in respect of, and shall each keep each




  
 46 














	 	
other fully informed of, all matters pertaining thereto, shall share copies of all material correspondence with any Tax Authority pertaining thereto and each shall notify the other as soon as
reasonably practicable when such removal has become effective. 

  

	15.2	 For any Tax Periods (or parts of Tax Periods) up to and including the Tax Period (or part Tax Periods) in which
the Tax Consolidations are split as mentioned in clause 15.1, GSK and Haleon shall (and shall procure that the members of their respective Groups shall) prepare and submit all Tax Returns and discharge Tax liabilities of each GSK Tax
Consolidation and Haleon Tax Consolidation (as applicable) according to their normal and ordinary course practice. 


  

	15.3	 In respect of any period in which a Haleon Group Company is or has been a member of a GSK Tax Consolidation,
and unless the same is inconsistent with normal and ordinary course practice, Haleon shall procure that the relevant Haleon Group Company pays to the appropriate GSK Group Company, an amount in respect of any liability to Tax which the relevant GSK
Group Company is primarily responsible for paying or discharging on behalf of, or in respect of Income, Profits or Gains of, or Events undertaken by, that Haleon Group Company except to the extent that: 



 

	 	(A)	 such contribution has already been made prior to Demerger Completion; or 



 

	 	(B)	 Haleon would (ignoring any limitations on liability under clause 4.8) be entitled to make a valid claim
under clause 2.1 of this Deed or Section 6.5(d)(ii) of the Cosmos SAPA in respect of such payment (if it were a liability to Tax of a Haleon Group Company) and, for the avoidance of doubt, no such claim shall be made by Haleon to the
extent that such Tax or payment is borne and discharged by a GSK Group Company. 


  

	15.4	 In respect of any period in which a GSK Group Company is or has been a member of a Haleon Tax Consolidation,
and unless the same is inconsistent with normal and ordinary course practice, GSK shall procure that the relevant GSK Group Company pays to the appropriate Haleon Group Company, an amount in respect of any liability to Tax which the relevant Haleon
Group Company is primarily responsible for paying or discharging on behalf of, or in respect of Income, Profits or Gains of, or Events undertaken by, that GSK Group Company except to the extent that: 



 

	 	(A)	 such contribution has already been made prior to Demerger Completion; or 



 

	 	(B)	 GSK would (ignoring any limitations on liability under clause 6.4) be entitled to make a valid claim
under clause 5.1 of this Deed (if it were a liability to Tax of a GSK Group Company) and, for the avoidance of doubt, no such claim shall be made by GSK to the extent that such Tax or payment is borne and discharged by a Haleon Group Company.



  

	15.5	 Haleon shall, or shall procure that each Haleon Group Company which is included in a US State Joint Tax Return
shall, pay to GSK (or the relevant GSK Group Company which files the US State Joint Tax Return in question) an amount equal to A multiplied by B, where: 


  

	 	(A)	 “A” is equal to the relevant Haleon Group Company’s separate taxable income divided by
the sum of the separate taxable income of all members with positive separate taxable income; and 



  
 47 














	 	(B)	 “B” is equal to the total amount of Tax due, as shown on the US State Joint Tax Return,



 for these purposes the term “separate taxable income” having the meaning given in US Treas. Reg. Section 1.1502-12 (or, as applicable, any similar provision of state or local laws or regulations). Payment shall not be required under this clause 15.5 to the extent that: 

 

	 	(i)	 such payment has already been made prior to Demerger Completion; or 



 

	 	(ii)	 Haleon would (ignoring any limitations on liability under clause 4.8) be entitled to make a valid claim
under clause 2.1 of this Deed or Section 6.5(d)(ii) of the Cosmos SAPA in respect of such payment (if it were a liability to Tax of a Haleon Group Company) and, for the avoidance of doubt, no such claim shall be made by Haleon to the
extent that such Tax or payment is borne and discharged by a GSK Group Company. 


  

	15.6	 Payments under clause 15.3 and clause 15.4 shall be made 10 Business Days before the date or
dates on which the Tax is due and payable to the appropriate Tax Authority for that period or otherwise on such date is consistent with normal and ordinary course practice. Payments under clause 15.5 shall be made on or before the date which
falls 20 Business Days after the date or dates on which the Tax is due and payable to the appropriate Tax Authority. 


  

	15.7	 Without prejudice to the remainder of this clause 15 or clause 13: 



 

	 	(A)	 GSK shall be responsible for the conducting correspondence with the applicable Tax Authority in respect of:



  

	 	(i)	 each GSK Tax Consolidation mentioned in clause 15.1; and 



 

	 	(ii)	 each US State Joint Tax Return, 



following Demerger Completion; and 
  

	 	(B)	 Haleon shall be responsible for the conducting correspondence with the applicable Tax Authority for each Haleon
Tax Consolidation mentioned in clause 15.1, 


 provided in all cases that GSK and Haleon shall (or shall procure
that the members of their respective Groups shall) keep each other fully informed of any matter relating thereto that affects a member of the other Group, including promptly sharing all related correspondence received from a Tax Authority (or
appropriate portions thereof). GSK and Haleon shall co-operate in good faith in order to agree how to resolve any such matter and shall (and shall procure that the members of their Groups shall) take into
account any reasonable comments of the other Group in relation thereto. 

  
 48 














	16.	 Post-Demerger Completion Conduct 



 

	16.1	 Haleon shall not, and shall procure that each member of the Haleon Group shall not, undertake or effect any
action described in Part A of Schedule 1 save that Haleon shall be permitted to take any action outlined in paragraph 3 in Part A of Schedule 1 provided that, prior to taking such action, Haleon shall have obtained
(i) a tax opinion in form and substance reasonably satisfactory to GSK, (ii) a private letter ruling, including any required supplemental ruling, from the U.S. Internal Revenue Service in form and substance reasonably satisfactory to GSK,
or (iii) GSK shall have waived in writing the requirement to obtain such tax opinion or private letter ruling. 


  

	16.2	 


  

	 	(A)	 Haleon shall not, and shall procure that each member of the Haleon Group shall not, undertake or effect any
action outlined in paragraph 2 to paragraph 7 (inclusive) in Part B of Schedule 1 save that Haleon shall be permitted to take any such action provided that, prior to taking such action, Haleon shall have obtained
(i) a tax opinion in form and substance reasonably satisfactory to Pfizer, (ii) a private letter ruling, including any required supplemental ruling, from the U.S. Internal Revenue Service in form and substance reasonably satisfactory to
Pfizer, or (iii) Pfizer shall have waived in writing the requirement to obtain such tax opinion or private letter ruling. For the avoidance of doubt, paragraph 3 in Part B of Schedule 1 is a representation as
to current plan or intention only and not a restriction on any actions of Haleon or any member of the Haleon Group. 


  

	 	(B)	 Prior to taking any action outlined in paragraph 8 in Part B of Schedule 1, Haleon shall
use commercially reasonable efforts to consult with Pfizer prior to such action to the extent it is not described in Schedule 2, provided further that nothing in this clause 16.2 shall interfere with the timing of any such
transaction or Haleon’s ability to pursue any such transaction in the manner and according to the schedule determined by Haleon in its sole discretion. 


  

	16.3	 The first [***] of Costs which are incurred by the Haleon Group in any one calendar year in respect of the
preparation and submission of any incremental Tax Returns or the provision of information or other similar administrative requirements in each case arising directly as a consequence of any of the matters listed in Part A of Schedule 1
shall be borne by such Haleon Group Companies, with GSK bearing any Cost in excess of such amount. 


  

	16.4	 The first [***] of Costs which are incurred by the Haleon Group in any one calendar year in respect of the
preparation and submission of any incremental Tax Returns or the provision of information or other similar administrative requirements in each case arising directly as a consequence of any of the matters listed in Part B of Schedule 1
shall be borne by such Haleon Group Companies, with Pfizer bearing any Cost in excess of such amount. 



  
 49 














	16.5	 Each of GSK and Haleon will co-operate and liaise with each other to
agree appropriate procedures and controls to be established within their respective Groups from Demerger Completion with the purpose of identifying, before they are made: 



 

	 	(A)	 any payments or transfers of money’s worth: 



 

	 	(i)	 by any GSK Group Company to any Haleon Group Company, any shareholder in Haleon or any shareholder in GSK or
any other GSK Group Company; or 


  

	 	(ii)	 by any Haleon Group Company to any GSK Group Company, any shareholder in GSK or any shareholder in Haleon or
any other Haleon Group Company; or 


  

	 	(B)	 any assumptions of liability: 



 

	 	(i)	 by any GSK Group Company from any Haleon Group Company, any shareholder in Haleon or any shareholder in GSK or
any other GSK Group Company; or 


  

	 	(ii)	 by any Haleon Group Company from any GSK Group Company, any shareholder in GSK or any shareholder in Haleon or
any other Haleon Group Company, 


 which in any such case may potentially constitute a Chargeable Payment in relation to
the Demerger and will co-operate and liaise with each other in relation thereto, including by obtaining appropriate professional advice in relation to such payments, transfers or assumptions and, where
appropriate, by seeking advance clearance from HM Revenue & Customs (“HMRC”) to ensure that such payments, transfers or assumptions do not constitute Chargeable Payments, provided in each case that if a Haleon Group Company
or a GSK Group Company intends to take any action which may potentially constitute a Chargeable Payment but which Haleon or GSK (respectively) reasonably believes HMRC have cleared as not being a chargeable payment pursuant to a prior advance
clearance, Haleon or GSK (respectively) shall not be required to liaise with the other in relation thereto prior to taking the relevant action.  
  

	17.	 Project Cosmos 



 

	17.1	 The Parties agree that, in view of GSKCHHL and JVCo ceasing to be controlled by GSK as a result of the
Demerger, it is necessary to amend the Cosmos SAPA as follows. 


 Definitions in the Cosmos SAPA 

 

	17.2	 The Parties agree to amend Section 1.1 (Definitions) of the Cosmos SAPA by adding the following
definitions, each to be effective as at Demerger Completion: 


 “Argentina Manufacturing Business”
shall have the meaning set forth in the Argentina NEBA; 

  
 50 













 “Argentina NEBA” shall have the meaning set forth in the
SCIA; 
 “Demerger Completion” shall have the meaning set forth in the SCIA; 

“Gold Tax Covenant” shall have the meaning given to the term “Tax Covenant” as set forth in the SCIA; 

“Gold Transaction Documents” shall have the meaning given to the term “Transaction Documents” as set
forth in the SCIA; 
 “Purchaser Parent Indemnifiable Tax Return” shall have the meaning set forth in
Section 6.5(a)(iiA);  
 “Purchaser
Pre-Closing Separate Tax Return” shall mean any Tax Return of the Purchaser or any of its Subsidiaries or their Subsidiaries (excluding the Conveyed Subsidiaries and their Subsidiaries) for any
Pre-Closing Tax Period other than any Straddle Period; 
 “Purchaser Straddle Period
Tax Return” shall mean any Tax Return of the Purchaser or any of its Subsidiaries or their Subsidiaries (excluding the Conveyed Subsidiaries and their Subsidiaries) for a Straddle Period;  

“SCIA” shall mean the Separation Co-operation and Implementation
Agreement entered into between GSK, Pfizer, Haleon, JVCo, GSKCHHL and PFCHHL; on or around 1 June 2022; 
 Preparation and Filing of
Tax Returns 
  

	17.3	 The Parties agree to amend the terms of Section 6.5(a) (Preparation and Filing of Tax Returns) of the
Cosmos SAPA as follows, each such amendment to be effective as at Demerger Completion. 


  

	 	(A)	 An additional Section 6.5(a)(iiA) shall be added immediately beneath Section 6.5(a)(ii) as
follows. 


 “ (iiA)    Any Tax Return (or relevant portion thereof) of Purchaser or any
of its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries after Closing) that includes or reflects (or is required to include or reflect) Purchaser Parent Indemnified Taxes for which Purchaser Parent would reasonably be expected
to be liable pursuant to this Agreement (any such Tax Return, or relevant portion thereof, a “Purchaser Parent Indemnifiable Tax Return”) shall be delivered by Purchaser to Purchaser Parent for its review, comment and
approval, at least thirty (30) days, in the case of Income Tax Returns, and fifteen (15) days, in the case of non-Income Tax Returns prior to the due date for the filing
of such Purchaser Parent Indemnifiable Tax Return (taking into account any  

  
 51 













 
applicable extensions), a statement setting forth the amount of Tax for which Purchaser Parent is responsible pursuant to
Section 6.5(d)(ii) and a copy of such Purchaser Parent Indemnifiable Tax Return, together with any additional information that Purchaser Parent may reasonably request. Purchaser Parent shall have
the right to review such Purchaser Parent Indemnifiable Tax Return, statement and any additional information prior to the filing of such Purchaser Parent Indemnifiable Tax Return, and Purchaser shall reflect on such Purchaser Parent Indemnifiable
Tax Return, as filed, any reasonable comments submitted by Purchaser Parent at least fifteen (15) days, in the case of Income Tax Returns, and five (5) days, in the case of
non-Income Tax Returns, prior to the due date of such Purchaser Parent Indemnifiable Tax Return (taking into account any applicable extensions) to the extent any such comments would not be reasonably expected
to result in Purchaser or its Subsidiaries being liable for any material Taxes that are not Purchaser Parent Indemnified Taxes for which Purchaser Parent is liable pursuant to this Agreement. Purchaser Parent shall, at least three
(3) days before any Tax Return that Purchaser is obligated to file is due, pay Purchaser (or a Subsidiary of Purchaser designated by Purchaser) the amount of Taxes shown as due thereon to the extent any such Taxes are Purchaser
Parent Indemnified Taxes.”. 
  

	 	(B)	 An additional Section 6.5(a)(iiiA) shall be added immediately beneath Section 6.5(a)(iii) as follows.



 “ (iiiA)    Neither Purchaser nor any of its Affiliates (including the Conveyed
Subsidiaries and their Subsidiaries) shall amend or revoke any Purchaser Pre-Closing Separate Tax Return or Purchaser Straddle Period Tax Return, or agree to any waiver or extension of the statute of
limitations, relating to Taxes with respect to Purchaser or any of its Subsidiaries (or any Subsidiary thereof) for a Pre-Closing Tax Period, without the prior written consent of Purchaser Parent (which
consent shall not be unreasonably withheld, conditioned or delayed). Upon Purchaser Parent’s reasonable request, at the sole cost and expense of Purchaser Parent, Purchaser shall file, or cause to be filed, any amended Purchaser Pre-Closing Separate Tax Return in the form and substance reasonably requested by Purchaser Parent and in a manner consistent with the past practices of the applicable Subsidiary of Purchaser (or its Subsidiary)
(other than as required as a result of the Purchaser Internal Restructurings), except to the extent that there is not at least a “more likely than not” basis for a position under applicable Law, provided that Purchaser
shall not be required to file any such amended Tax Return to the extent it would reasonably be expected to result in Purchaser or its Subsidiaries being liable for any material Taxes that are not Purchaser Parent Indemnified Taxes for which
Purchaser Parent is liable pursuant to this Agreement or otherwise result in commercial consequences that materially and adversely affect Purchaser.”. 

Tax indemnification provisions under the Cosmos SAPA 
  

	17.4	 The Parties agree to amend the terms of Section 6.5(d) (Tax Indemnification) of the Cosmos SAPA as
follows, such amendment to be effective as at Demerger Completion. 



  
 52 














	 	(A)	 An additional provisos shall be added to the existing Section 6.5(d)(ii) as marked below.



 “...; provided that Purchaser Parent shall not be required to indemnify or hold
harmless any Purchaser Tax Indemnified Party from and against any liability for (AA) Taxes attributable to any action taken after Demerger Completion by Purchaser, or any of its Affiliates (including the Conveyed Subsidiaries and their
Subsidiaries), or any transferee of Purchaser or any of its Affiliates (including the Conveyed Subsidiaries and their Subsidiaries), other than any such action that (1) is in the ordinary course of business,
(2) is expressly permitted or contemplated by this Agreement, or (3) is required to be taken in order to comply with applicable Law or as a result of a change in applicable
Law, (A) Taxes attributable to any action taken after Closing by Seller Parent or any of its Affiliates...”. 

“...or (D) Taxes for which Seller Parent is responsible under
Section 6.5(d)(i), or (E) any Taxes of Argentina S.A. in respect of the Argentina Manufacturing Business to the extent arising on or after, or referable to any period on or after, the
“Commencement Date” (as that term is defined in the Argentina NEBA).”. 
 Conduct of Tax Authority Claims relevant to the
Cosmos SAPA 
  

	17.5	 The Parties agree to amend the terms of Section 6.5(e) (Tax Contests) of the Cosmos SAPA as follows, such
amendments to be effective as at Demerger Completion. 


  

	 	(A)	 A new Section shall be inserted immediately beneath the current Section 6.5(e)(ii) as follows.



 “(iiA)    With respect to any Tax Claim within
Section 6.5(e)(ii), Seller Parent shall also (x) notify Purchaser Parent of any material development with respect to any such Tax Proceeding, (y) provide Purchaser Parent with copies of any
material documents submitted in connection with such Tax Proceeding and (z) notify Purchaser Parent regarding any material action to be taken by Seller Parent with respect to such Tax Proceeding (and take Purchaser Parent’s
comments into consideration in good faith), in each case, solely to the extent relating to matters or aspects of such Tax Proceeding that would reasonably be expected to materially increase any Purchaser Parent Indemnified Taxes or any liability of
the Purchaser Parent under the Gold Tax Covenant.”.  
  

	 	(B)	 A new Section shall be inserted immediately beneath Section 6.5(e)(iiA) (as inserted by clause
17.5(A)) as follows. 


 “(iiB)    With respect to any Tax Claim relating to
Purchaser or any Subsidiary thereof (other than the Conveyed Subsidiaries and their Subsidiaries) for any Tax period ending on or before the Closing Date, to Purchaser Parent (or any Subsidiary thereof) for any taxable period, or with respect to a
Purchaser Parent Combined Tax Return, Purchaser Parent shall control all Tax Proceedings and shall make all decisions taken in connection with such Tax Proceeding (including  

  
 53 













 
selection of counsel), and, without limiting the foregoing, may pursue or forego any and all administrative appeals, proceedings, hearings and conferences with any Taxing Authority with
respect thereto, and may either pay the applicable Tax Liability and sue for a refund or contest the Tax Claim; provided, that in the case of such Tax Proceeding with respect to a Tax Return of Purchaser or a Subsidiary thereof
(other than a Conveyed Subsidiary or Subsidiary thereof) other than a Purchaser Parent Combined Tax Return, Purchaser Parent shall not settle such Tax Proceeding if doing so would reasonably be expected to materially increase the Tax Liability of
Purchaser or its Subsidiaries (including the Conveyed Subsidiaries and any Subsidiary thereof after the Closing), taking into account any indemnification for Tax Liabilities under this Agreement, without the prior written consent of Purchaser, which
consent shall not be unreasonably withheld, delayed or conditioned. In the case of any such Tax Proceeding with respect to Purchaser or a Subsidiary thereof (other than the Conveyed Subsidiaries and their Subsidiaries), Purchaser Parent shall
(x) notify Purchaser of any material development with respect to any such Tax Proceeding, (y) provide Purchaser with copies of any material documents submitted in connection with such Tax Proceeding and
(z) notify Purchaser regarding any material action to be taken by Purchaser Parent with respect to such Tax Proceeding (and take Purchaser’s comments into consideration in good faith), in each case, solely to the extent
relating to matters or aspects of such Tax Proceeding that would reasonably be expected to materially increase the Tax Liability of Purchaser or a Subsidiary thereof (other than the Conveyed Subsidiaries and their Subsidiaries) in a Post-Closing Tax
Period ”. 
  

	 	(C)	 A new Section shall be inserted immediately beneath the Section 6.5(e)(iiB) (as inserted by clause
17.5(B)) as follows. 


 “(iiC)    With respect to any Tax Claim within
Section 6.5(iiB), Purchaser Parent shall also (x) notify Seller Parent of any material development with respect to any such Tax Proceeding, (y) provide Seller Parent with copies of any
material documents submitted in connection with such Tax Proceeding and (z) notify Seller Parent regarding any material action to be taken by Purchaser Parent with respect to such Tax Proceeding (and take Seller Parent’s
comments into consideration in good faith), in each case, solely to the extent relating to matters or aspects of such Tax Proceeding that would reasonably be expected to materially increase any Seller Indemnified Taxes or any liability of the Seller
Parent under the Gold Tax Covenant.”.  
  

	 	(D)	 A new Section shall be inserted immediately beneath the current Section 6.5(e)(iii) as follows.



 “(iiiA)    Section 6.5(e)(iii) above shall apply in the case of any Tax Proceeding
relating to Taxes of Purchaser or its Subsidiaries (other than the Conveyed Subsidiaries (and their Subsidiaries)) for any Straddle Period, and for such purposes any reference to “Seller Parent” shall be replaced with a reference to
“Purchaser Parent.”. 

  
 54 














	 	(E)	 The existing Section 6.5(e)(iv) shall be amended as marked below. 



“Except as otherwise provided herein, Purchaser shall control all Tax Proceedings with respect to Purchaser and its
Subsidiaries (including the Conveyed Subsidiaries (and their Subsidiaries)) for any taxable period beginning after the Closing Date and any Tax Proceeding with respect to Purchaser or any of its Affiliates relating to
(x) any Seller Indemnifiable Tax Return or (y) any Purchaser Parent Indemnifiable Tax Return; provided that (in relation to a Seller
Indemnifiable Tax Return) Seller Parent or (in relation to a Purchaser Parent Indemnifiable Tax Return) Purchaser Parent, shall be deemed to be a Non-Controlling Party (with the
rights described in Section 6.5(e)(iii) or Section 6.5(e)(iiiA) as the case may be) with respect to any such Tax Proceeding if the resolution of any such Tax Proceeding would
reasonably be expected to materially increase the Tax Liability of a Purchaser or any of its Subsidiaries (including any Conveyed Subsidiary (or a Subsidiary thereof)) in a Pre-Closing Tax
Period or (as applicable) the amount of indemnification for which Seller Parent is responsible pursuant to Section 6.5(d)(i) or for which Purchaser Parent is responsible pursuant to
Section 6.5(d)(ii).”. 
  

	 	(F)	 The existing Section 6.5(e)(v) shall be amended by inserting “(or Purchaser Parent and its
Affiliates, as the case may be)” after the words “Seller Parent and its Affiliates” where they first appear in the provision. 



Other 
  

	17.6	 Neither GSK nor Pfizer shall be liable under Section 6.5(d) of the Cosmos SAPA in respect of an individual
claim for less than [***], but once the amount of any such claim has exceeded such sum, GSK or Pfizer (as applicable) shall be liable in respect of the full amount of such claim and not only the amount by which such sum is exceeded. For the purposes
of this clause 17.6, individual claims arising out of the same or substantially the same matters, facts or circumstances shall be aggregated so as to be treated as a single claim. 



 

	18.	 Anti-hybrid rules and interest restriction rules 



 

	18.1	 Subject to Clause 18.2, Clauses 7.1 to 7.5 of the Cosmos SCA and any relevant definitions shall be
treated as continuing to apply in respect of any period or part period prior to Demerger Completion as though those provisions of the Cosmos SCA (and any related definitions) had remained in effect, and as though references to “Company”
and “Company’s Group” therein were references to “Haleon” and “Haleon Group”, respectively, as defined in this Deed as the context demands. 



 

	18.2	 Pfizer shall have no liability in respect of any claim under Clauses 7.1 to 7.5 of the Cosmos SCA unless and
until the aggregate amount of Pfizer’s liability thereunder in the absence of this clause 18.2 would have exceeded [***], in which event Pfizer shall thereafter be liable for such amounts which exceed that [***] threshold (and not for
the full amount of such claim or claims) up to a total liability of Pfizer of [***]. 



  
 55 














	19.	 Miscellaneous 



 

	19.1	 Save where required to be made on an after-Tax basis (in which case
clause 1.2(O) shall apply), payments due to be made under this Deed shall be made free and clear of all deductions, withholdings, set-offs, or counterclaims whatsoever, except as may be required by Law.
If any deductions or withholdings are required by Law, the paying party shall be obliged to pay such sum as will, after such deduction, withholdings, set-off or counter-claim has been made, leave the receiving
party with the same amount as it would have been entitled to receive in the absence of any such requirement to make such deduction or withholding.  


  

	19.2	 Where any party to this Deed is required, as a result of clause 1.2(O) or clause 19.1 to increase
any payment it would otherwise be required to make, the additional amount payable as a result of clause 1.2(O) or clause 19.1 (as applicable) shall not exceed what it would have been had the recipient been resident for all Tax purposes
solely in its jurisdiction of incorporation (and not had a permanent establishment or other taxable presence in any other place). 


  

	19.3	 Any payment made by a Party under this Agreement shall (so far as legally permitted) be treated as an
adjustment to the consideration for the shares transferred pursuant to the Demerger Agreement or applicable Exchange Agreement to the extent of the payment. 


  

	19.4	 Where it is agreed or determined that an amount is payable by one Party to another in respect of any covenant,
balancing payment or indemnity given under this Deed, the SCIA, an Exchange Agreement or the Demerger Agreement, those Parties shall consult in good faith for a period of not less than 10 Business Days (or such longer or shorter period as the
affected Parties may agree, and without prejudice to clause 9 and clause 19.5) with a view to agreeing an acceptable arrangement for satisfying the obligation to pay the amount so claimed in an efficient manner that does not
prejudice the Parties’ or their Groups’ respective interests. Without limitation, and by way of example only, the Parties may consider directing that payments are not made by one Party to the other but instead are made by a subsidiary
within the paying Party’s Group to a subsidiary within the recipient Party’s Group. If the affected Parties fail to agree on any particular manner of payment during the course of such consultations (but not before), the Party which is
liable to make the payment shall make that payment in cash in accordance with the remaining terms of this Deed. 


  

	19.5	 [Unless otherwise agreed in writing between the Party obliged to make and the Party entitled to receive the
payment in question, payments under this Deed shall be made in Sterling. Where the underlying matter giving rise to a claim under this Deed comprises an amount which is or would not be in Sterling, the Sterling equivalent shall be determined based
on the Bloomberg BFIX rate in effect as of 3:00 pm (London time) two (2) Business Days preceding the date of the written notice given for such claim.] 


  

	19.6	 Payments due to be made under this Deed shall, if not paid within thirty (30) days of the due date, and
except to the extent the liability giving rise to the payment compensates the recipient for late payment by virtue of its extending to interest and penalties, carry interest at a rate of (i) two (2) per cent. above the base lending rate
from time to time of 



  
 56 














	 	
the Bank of England, or (ii) if such base lending rate is less than zero, at two (2) per cent. (the “Agreed Rate”) for the period from the date falling thirty
(30) days after the due date to the date of actual payment. 

  

	19.7	 This Deed is conditional on the passing of the Demerger Resolution and the Related Party Transactions
Resolution by GSK Shareholders at the GSK General Meeting (as all such terms are defined in the Demerger Agreement). 


  

	19.8	 Save for those provisions expressly stated to come into effect at a different time, this Deed shall come into
effect from Demerger Completion. 


  

	19.9	 The provisions of clauses 16 (Confidentiality), 22 (Notices), 25 (Assignment), 26 (Remedies and Waivers), 27
(Variation), 30 (Invalidity), 32 (Counterparts), 33 (Language) and 35 (Agent for Service) of the SCIA shall apply for the purposes of this Deed as if set out herein in full mutatis mutandis. 



 

	20.	 Costs and Expenses 



 

	20.1	 Each Party agrees to the apportionment of Costs as set out in clause 19 (Costs and Expenses) of the SCIA.



  

	20.2	 In relation to any Costs not addressed by clause 20.1, except as otherwise set out in this Deed, the
Cosmos SHA or the SCIA, each Party shall pay its own Costs incurred in relation to the negotiation, preparation, execution and carrying into effect of this Deed. 



 

	21.	 Governing Law and Jurisdiction 



 

	21.1	 This Deed is to be governed by and construed in accordance with English law. Any matter, claim or dispute
arising out of or in connection with this Deed, whether contractual or non-contractual, is to be governed by and determined in accordance with English law. 



 

	21.2	 The courts of England are to have exclusive jurisdiction to settle any dispute arising out of or in connection
with this Deed. Any Proceedings shall be brought only in the courts of England. 


  

	21.3	 Each Party waives (and agrees not to raise) any objection, on the ground of forum non conveniens or on
any other ground, to the taking of proceedings in the courts of England. Each Party also agrees that a judgment against it in Proceedings brought in England shall be conclusive and binding upon it and may be enforced in any other jurisdiction.




  
 57 













 Schedule 1 

Post-Demerger Completion Conduct 

Part A 
  

	1	 At the time of Demerger Completion, neither Haleon nor any member of the Haleon Group shall have any current
plan or intention to: 


  

	 	(A)	 sell, dispose, or otherwise transfer any of the assets of the ATB Companies other than (i) in the ordinary
course of business, (ii) to another member of the Separate Affiliated Group of Haleon, (iii) cash paid to acquire assets from unrelated person in arm’s length transaction, or (iv) cash paid to effect a mandatory or optional
repayment of indebtedness of Haleon or any member of the Haleon Group. For these purposes, Haleon’s “Separate Affiliated Group” shall mean one or more chains of entities which are classified as corporations for U.S. federal
income tax purposes connected through share ownership with Haleon in which (i) Haleon owns directly, for U.S. federal income tax purposes, stock of at least one other member of the group (a) possessing at least 80 per cent. of the
voting power of the stock of such member and (b) having a value equal to at least 80 per cent. of the total value of the stock of such member and (ii) one or more members of the group own directly, for U.S. federal income tax
purposes, stock of each other member of the group (except Haleon) (a) possessing at least 80 per cent. of the voting power of the stock of such member and (b) having a value equal to at least 80 per cent. of the total value of
the stock of such member. For purposes of determining share ownership, the term “stock” does not include stock that (1) is not entitled to vote, (2) is limited and preferred as to dividends and does not participate in corporate
growth to any significant extent, (3) has redemption and liquidation rights that do not exceed the issue price of such stock (except for a reasonable redemption premium or liquidation premium), and (4) is not convertible into another class
of stock; 


  

	 	(B)	 sell, dispose, otherwise transfer any equity interest in any of the ATB Companies , or take any action that
would cause GSKCHH 3 to cease to be a member of Haleon’s Separate Affiliated Group; 


  

	 	(C)	 change the U.S. federal income tax classification of any of the ATB Companies, including through the issuance
of additional equity interests in any ATB Company that is a disregarded entity for U.S. federal income tax purposes to an entity other than its sole owner for U.S. federal income tax purposes; 



 

	 	(D)	 fail to continue the conduct of the significant management and operational activities of the ATB Companies with
employees of GlaxoSmithKline Consumer Healthcare (UK) Trading Limited and other ATB Companies and members of Haleon’s Separate Affiliated Group in a substantially similar manner as they were conducted during the five-year period preceding the
Demerger (taking into account the activities of (i) GlaxoSmithKline Caribbean Limited in the case of 



  
 58 














	 	
GlaxoSmithKline Panama S.A. (“GSK Panama”), GSK CH Caricam Sociedad de Responsabilidad Limitada, and GSK Consumer Healthcare Trinidad and Tobago Limited and
(ii) GlaxoSmithKline Pte Ltd. in the case of GlaxoSmithKline Consumer Healthcare Vietnam Company Limited); or 

  

	 	(E)	 adopt a plan or enter into any agreement to do any of the actions set forth in the foregoing paragraphs
(A) through (D) (any action described in paragraphs (A) through (E), a “Potential CH ATB Restructuring”). 


  

	2	 At the time of the Demerger Completion, neither Haleon nor any member of the Haleon Group shall have any
current plan or intention to: 


  

	 	(A)	 voluntarily merge, consolidate, liquidate, or dissolve (including for U.S. federal income tax purposes) Haleon,
GSKCHHL, JVCo, GlaxoSmithKline Consumer Healthcare Holdings (US) Inc. (“GSKCHH-US”), SmithKline Beecham Research Limited (“SBRL”), or Sterling Products International, Inc.
(“SPII”); provided, for the avoidance of doubt, that for purposes of this paragraph 2(A), the terms “merge” and “consolidate” shall mean a transaction or series of transactions in which, for U.S. federal income
tax purposes, all of an existing entity’s assets and liabilities are transferred to one or more other entities and such existing entity ceases to exist as a regarded entity; 



 

	 	(B)	 convert Haleon, GSKCHHL, JVCo, GSKCHH-US, SBRL, or SPII into another
form of entity or to change its classification for U.S. federal income tax purposes; 


  

	 	(C)	 take any action that would result in the involuntary merger, liquidation, bankruptcy, dissolution, or winding
up of the affairs of Haleon, GSKCHHL, JVCo, GSKCHH-US, SBRL, or SPII; provided, for the avoidance of doubt, that for purposes of this paragraph 2(C), the term “merger” shall mean a transaction or
series of transactions in which, for U.S. federal income tax purposes, all of an existing entity’s assets and liabilities are transferred to one or more other entities and such existing entity ceases to exist as a regarded entity;



  

	 	(D)	 change the direct ownership of GSKCHHL, JVCo, GSKCHH-US, or SPII other
than through transactions that are disregarded for U.S. federal income tax purposes; 


  

	 	(E)	 transfer assets owned, directly or indirectly, by any member of the
GSKCHH-US Consolidated Group to a related person that is also not a member of the GSKCHH-US Consolidated Group, other than in the ordinary course of business (and for
these purposes the “GSKCHH-US Consolidated Group” means the affiliated group of U.S. corporations of which GSKCHH-US is the common parent that join in
the filing of a consolidated U.S. federal income tax return); or 


  

	 	(F)	 transfer assets owned, directly or indirectly, by SPII to a related person, other than in the ordinary course
of business; or 


  

	 	(G)	 issue or transfer shares to any member of the Pfizer Group that would result in the Pfizer Group, in the
aggregate, directly or indirectly owning more than 50 percent of the stock (by vote or value) of any member of the Haleon Group (any action described in paragraphs (A) through (G) above, a “Restricted US Transfer”).




  
 59 














	3	 Prior to the two-year anniversary of the Demerger Completion, neither
Haleon nor any member of the Haleon Group shall take any action (including the adoption of a plan or arrangement) to effect any: 


  

	 	(A)	 Potential CH ATB Restructuring; 



 

	 	(B)	 Restricted US Transfer; or 



 

	 	(C)	 redemption or other repurchase, directly or through any member of the Haleon Group, of any Haleon shares (or of
rights to acquire any Haleon shares) after the Demerger, other than repurchases or redemptions of widely held Haleon shares that (i) are made in the open market, (ii) are motivated by a non-U.S.
federal income tax purpose and (iii) in the aggregate, do not exceed 20 percent of the outstanding Haleon shares. For purposes of this provision, a redemption or other repurchase includes acquisitions of Haleon shares by any trusts that
are maintained by any member of the Haleon Group for the purpose of satisfying equity compensation awards to employees of the Haleon Group (other than pursuant to a direct subscription for such shares by any such trusts from Haleon).




  
 60 













 Part B 
  

	1	 In this Part B the following expressions shall have the following meanings: 



 

			
	 “Haleon NVPS”
	 	has the meaning given to the term “Haleon NVPS” in the Pfizer Exchange Agreement;
		
	 “Haleon NVPS Holder”
	 	means the person who purchases the Haleon NVPS from a Pfizer Group Company and any subsequent holder of such stock;
		
	 “NVPS Sale”
	 	has the meaning given to the term “NVPS Sale” in the Pfizer Exchange Agreement; and
		
	 “Code”
	 	means the U.S. Internal Revenue Code of 1986, as amended.

  

	2	 Neither Haleon nor any member of the Haleon Group shall (i) at the time of the Demerger Completion, have
any current plan or intention to, and (ii) prior to the two-year anniversary of the Demerger Completion, cause or permit: 



 

	 	(A)	 GSK Consumer Healthcare Holdings (No.1) Limited (“GSKCHH 1”) or GSKCHH 3 to (i) issue new
shares of stock (whether or not in exchange for property), (ii) reacquire (or redeem or cancel, whether or not in exchange for property) or convert (or recapitalize) any of its outstanding shares of stock, or (iii) amend its organization
documents to take any other action affecting the voting rights of its outstanding shares of stock; 


  

	 	(B)	 Any of the equity interests in GSKCHH-US to be recapitalized
into a different class of equity; 


  

	 	(C)	 GSKCHH-US to reacquire (or redeem or cancel, whether or not in exchange
for property) or convert (or recapitalize) any of its issued and outstanding preferred stock; 


  

	 	(D)	 GSK Panama or GSKCHH-US to acquire any of the outstanding shares of
GSKCHH 1 common stock or GSKCHH 3 common stock or GSKCHH-US to dispose of any of its shares of nonvoting preferred shares of GSKCHH 1 (“GSKCHH 1 NVPS”) or GSKCHH 3 (“GSKCHH 3
NVPS”); 



  
 61 














	 	(E)	 GSK Panama or GSK Consumer Healthcare Holdings (No.7) Limited (“GSKCHH 7”) to reacquire any of
the GSKCHH 1 NVPS or GSKCHH 3 NVPS; 


  

	 	(F)	 To take any action that would result in the involuntary merger, liquidation, bankruptcy, dissolution, or
winding up of the affairs of GSKCHH 1, GSKCHH 3, GSKCHH-US, or GSKCHH 7, or otherwise cease such entity’s legal existence; 



 

	 	(G)	 GSKCHH 1, GSKCHH 3, GSKCHH 7, Consumer Healthcare Intermediate Holdings Ltd., or Consumer Healthcare Holdings
Ltd. to liquidate, combine with another entity (whether in a reorganization or otherwise), convert into another form of entity or change its classification for U.S. federal income tax purposes; or 



 

	 	(H)	 GSKCHH 7 to sell, exchange, or otherwise dispose of, except in the ordinary course of business, any of its
(i) equity interests in GSKCHH 1, (ii) equity interests in GSKCHH 6, (iii) equity interests in Ferrosan ApS, or (iv) equity interests in SBRL. 


  

	3	 Neither Haleon nor any member of the Haleon Group shall, as of the time of the Demerger Completion, have any
current plan or intention to contribute any property to GSKCHH-US Inc. 


  

	4	 Haleon will not and will not cause any of its affiliates to discharge GSKCHH 1’s obligation on the notes
issued by GSKCHH1 to JVCo on November 22, 2021 (“GSKCHH 1 Notes”) prior to maturity, whether via a contribution of the GSKCHH 1 Notes by JVCo (or any affiliated entity) to the capital of GSKCHH 1 or otherwise, or to take any
other action that would result in the cancellation of the GSKCHH 1 Notes, other than payments in accordance with the terms of the GSKCHH 1 Notes. 


  

	5	 Neither Haleon nor any member of the Haleon Group shall (i) at the time of the NVPS Sale, have any current
plan or intention to, and (ii) prior to the five-year anniversary of the NVPS Sale, cause or permit: 


  

	 	(A)	 An amendment of the terms, or any other action affecting the voting rights (or lack thereof), of the Haleon
NVPS; 


  

	 	(B)	 The Haleon NVPS to be reacquired (or redeemed or cancelled, whether or not in exchange for property) or
converted (or recapitalized), except for a redemption pursuant to the terms, as of issuance, of the Haleon NVPS; or 


  

	 	(C)	 An issuance of any (A) additional shares of the Haleon NVPS or (B) additional nonvoting stock that
may be treated as the same class of stock as the Haleon NVPS. 


  

	6	 Prior to the two-year anniversary of the Demerger Completion, neither
Haleon nor any member of the Haleon Group shall take any action (including the adoption of a plan or arrangement) to: 


  

	 	(A)	 voluntarily merge, consolidate, liquidate, or dissolve (including for U.S. federal income tax purposes) JVCo;




  
 62 














	 	(B)	 convert JVCo into another form of entity or to change its classification for U.S. federal income tax purposes
(including, for the avoidance of doubt, as a result of a contribution of the equity interests in JVCo to an entity classified as a corporation for U.S. federal income tax purposes); 



 

	 	(C)	 take any action that would result in the involuntary merger, liquidation, bankruptcy, dissolution, or winding
up of the affairs of JVCo; or 


  

	 	(D)	 change the direct ownership for U.S. federal income tax purposes (including by contribution or redemption) of
JVCo other than through transactions that are disregarded for U.S. federal income tax purposes. 


  

	7	 Prior to the later of (i) the two-year anniversary of the Demerger
Completion and (ii) the first day of the succeeding U.S. federal income tax year of the relevant member of the Haleon Group after the first taxable year in which Pfizer or any member of Pfizer’s Group would no longer be subject to the PFIC
rules under Sections 1291 to 1298 of the Code if Haleon or any member of the Haleon Group were to constitute a PFIC (as defined in Section 1297 of the Code), Haleon will use commercially reasonable efforts to cause Haleon and each member of the
Haleon Group not to constitute a PFIC. 


  

	8	 An action is outlined in this paragraph 8 if, prior to the later of (i) the
two-year anniversary of the Demerger Completion and (ii) the first day of the succeeding U.S. federal income tax year of the relevant member of the Haleon Group after the first taxable year in which
neither Pfizer nor any member of Pfizer’s Group constitutes a “United States shareholder” as defined in Section 951(b) of the Code of such member of the Haleon Group, a member of the Haleon Group shall: 



 

	 	(A)	 Take any action or series of related actions outside the ordinary course of business (including a change in the
entity classification of any member of the Haleon Group for U.S. federal, state or local tax purposes), which would reasonably be expected to cause any member of the Haleon Group, or any member of the Pfizer Group, to recognize a material amount of
income under Section 951(a) or 951A(a) of the Code. 


  

	 	(B)	 Acquire any material asset outside the ordinary course of business that constitutes “United States
property” within the meaning of Section 956 of the Code (including by entering into credit support arrangements that are treated as investments in “United States property” within the meaning of Section 956 of the Code) and
that would reasonably be expected to give rise to a material gross income inclusion to any member of the Pfizer Group under Section 951(a)(1)(B) of the Code. 



  
 63 













 Schedule 2 

White List 
  

	(A)	 Any transaction, arrangement or agreement with, or disposition, transfer, sale, exchange or disposal to, or
acquisition from, a third party for cash; 


  

	(B)	 Any transaction, arrangement, agreement, disposition, acquisition, transfer, sale, exchange, disposal,
restructuring, reorganisation, action or other step required to be entered into in order to obtain any consent, approval or authorisation of, permit or licence issued or granted by, governmental order, waiver or exemption by, any person (including
any governmental authority) or which is otherwise required by any governmental antitrust authority; 


  

	(C)	 Any transaction, arrangement, agreement, disposition, acquisition, transfer, sale, exchange, disposal,
restructuring, reorganisation, action or other step between one or more members of the Haleon Group that are treated as entities disregarded as separate from each other for U.S. federal income Tax purposes and which are direct or indirect
subsidiaries of the same member of the Haleon Group that is treated as a corporation for U.S. federal income Tax purposes. 



  
 64 













 IN WITNESS of which this document has been executed as a deed and delivered on the date stated at the
beginning hereof. 
  

					
	SIGNED as a DEED by DAVID REDFERN as attorney for GSK PLC in the presence of:	  	)
 )
 )

)
 )
	  	 /s/ David Redfern

(Signature of attorney)
 DAVID REDFERN as attorney for
GSK PLC

			
	Witness’s signature:	  		  	 /s/ Diane Hewett

			
	Name (print):	  		  	 Diane Hewett

			
	Occupation:	  		  	 Homemaker

			
	Address:	  		  	      



  
 65 














					
	 EXECUTED as a DEED by PFIZER INC.
acting by DEBORAH BARON

who, in accordance with the laws of the territory in which PFIZER INC. is incorporated, is acting under
the authority of PFIZER INC.
	  	)
 )
 )

)
 )

)
 )

)
	  	 /s/ Deborah Baron

(Authorised signatory)



  
 66 














					
	SIGNED as a DEED by AMANDA MELLOR as attorney for HALEON PLC in the presence of:	  	)
 )
 )

)
 )
	  	 /s/ Amanda Mellor

(Signature of attorney)
 AMANDA MELLOR as attorney for

HALEON PLC

			
	Witness’s signature:	  		  	 /s/ Bridget Creegan

			
	Name (print):	  		  	 Bridget Creegan

			
	Occupation:	  		  	 Chartered Company Secretary

			
	Address:	  		  	      



  
 67 














					
	EXECUTED as a DEED by GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (NO.2) LIMITED acting by DAVID REDFERN, a director, in the presence of: 	  	)
)
)
)
)	  	 /s/ David Redfern

Director

			
	Witness’s signature:	  		  	 /s/ Diane Hewett

			
	Name (print):	  		  	 Diane Hewett

			
	Occupation:	  		  	 Homemaker

			
	Address:	  		  	      



  
 68 














					
	SIGNED as a DEED by DAVID REDFERN as attorney for GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED in the presence of:	  	)
)
)
)
)
)	  	 /s/ David Redfern

(Signature of attorney) 
 DAVID REDFERN as attorney for
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LIMITED

			
	Witness’s signature:	  		  	 /s/ Diane Hewett

			
	Name (print):	  		  	 Diane Hewett

			
	Occupation:	  		  	 Homemaker

			
	Address:	  		  	      



  
 69